

C:\Program Files\Common Files\System\Mapi\1033\NT





chain nodes :
7 8
ring nodes :
1 2 3 4 5 6 9 10 11 12 13
ring/chain nodes :
15
chain bonds :
3-7 5-8 7-11 8-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-13 10-11 11-12 12-13
exact/norm bonds :
3-7 5-8 7-11 8-15 9-10 9-13 10-11 11-12 12-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 15:CLASS

```
=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end



=> screen 1839

L1    SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L2    SCREEN CREATED

=>
Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10026992.str
```




```
chain nodes :
7  8
ring nodes :
1  2  3  4  5  6  9  10  11  12  13
chain bonds :
3-7  5-8
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  9-10  9-13  10-11  11-12  12-13
exact/norm bonds :
3-7  5-8  9-10  9-13  10-11  11-12  12-13
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 : 9 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:CLASS




L3       STRUCTURE UPLOADED
```

```
=> que L3 AND L1 NOT L2

L4   QUE L3 AND L1 NOT L2

=> d l4
L4 HAS NO ANSWERS
L1              SCR 1839
L2              SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L3              STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L4              QUE  L3 AND L1 NOT L2


=> s l4 sss sam
SAMPLE SEARCH INITIATED 08:00:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    166 TO ITERATE

100.0% PROCESSED     166 ITERATIONS                          23 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         2547 TO     4093
PROJECTED ANSWERS:             173 TO      747

L5           23 SEA SSS SAM L3 AND L1 NOT L2

=> => ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end



=> screen 1839

L6    SCREEN CREATED
```

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L7 SCREEN CREATED

=>
Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10026992 (2).str



chain nodes :
7 8
ring nodes :
1 2 3 4 5 6 9 10 11 12 13
ring/chain nodes :
16
chain bonds :
3-7 5-8 8-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-13 10-11 11-12 12-13
exact/norm bonds :
3-7 5-8 8-16 9-10 9-13 10-11 11-12 12-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 16:CLASS


L8 STRUCTURE UPLOADED

=> que L8 AND L6 NOT L7

L9 QUE L8 AND L6 NOT L7

=> d l9

L9 HAS NO ANSWERS
L6 SCR 1839
L7 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L8 STR



Structure attributes must be viewed using STN Express query preparation.
L9 QUE L8 AND L6 NOT L7

=> s l9 sss sam
SAMPLE SEARCH INITIATED 08:03:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 166 TO ITERATE

100.0% PROCESSED 166 ITERATIONS 24 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2547 TO 4093
PROJECTED ANSWERS: 186 TO 772

L10 24 SEA SSS SAM L8 AND L6 NOT L7

=> => Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1839

L11 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L12 SCREEN CREATED

=>
Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10026992 (3).str



chain nodes :
7 8
ring nodes :
1 2 3 4 5 6 9 10 11 12 13
ring/chain nodes :
15
chain bonds :
3-7 5-8 7-11 8-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-13 10-11 11-12 12-13
exact/norm bonds :
3-7 5-8 7-11 8-15 9-10 9-13 10-11 11-12 12-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 15:CLASS

L13 STRUCTURE UPLOADED

=> que L13 AND L11 NOT L12

L14 QUE L13 AND L11 NOT L12

=> d l14
L14 HAS NO ANSWERS
L11 SCR 1839
L12 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L13 STR



Structure attributes must be viewed using STN Express query preparation.
L14 QUE L13 AND L11 NOT L12

=> s l14 sss sam
SAMPLE SEARCH INITIATED 08:05:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 48 TO ITERATE

100.0% PROCESSED 48 ITERATIONS 23 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 545 TO 1375
PROJECTED ANSWERS: 173 TO 747

L15 23 SEA SSS SAM L13 AND L11 NOT L12

=> s l14 sss ful
FULL SEARCH INITIATED 08:06:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 962 TO ITERATE

100.0% PROCESSED 962 ITERATIONS 518 ANSWERS
SEARCH TIME: 00.00.01

L16 518 SEA SSS FUL L13 AND L11 NOT L12

=> => s l16
L17 11 L16


=> d l17 1-11 bib,ab,hitstr

L17 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:454299 CAPLUS
DN 139:36535
TI Preparation of pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (IGF-1)
IN Barlaam, Bernard; Pape, Andrew; Thomas, Andrew
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048133	A1	20030612	WO 2002-SE2221	20021203

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


PRAI SE 2001-4140 A 20011207
OS MARPAT 139:36535
AB Pyrimidinediamines I [R1, R4 = (un)substituted heteroarom.; R2 = alkyl, haloalkyl, hydroxyalkyl, alkoxy (sic); R3 = H, halogen, CF3] were prepared for use as modulators of IGF-1 in the treatment of cancer with IC50 in the IGF-1R kinase assay of ≤ 100 μM and in the IGF-stimulated cell proliferation test of ≤ 50 μM. Thus, 5-bromo-2,4-dichloropyrimidine was treated with 3-amino-5-methyl-1H-pyrazole, followed by 5-aminomethyl-3-methylisoxazole hydrochloride to give the diamine II.
IT **543712-73-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidine derivs. as modulators of insulin-like growth factor-1 receptor (IGF-1))
RN 543712-73-8 CAPLUS
CN 3-Isoxazolecarboxylic acid, 5-[[[5-bromo-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
IT **543710-62-9P 543710-64-1P 543710-66-3P**


543710-68-5P 543710-71-0P 543710-73-2P
543710-75-4P 543710-77-6P 543710-79-8P
543710-81-2P 543710-83-4P 543710-85-6P
543710-87-8P 543710-89-0P 543710-91-4P
543710-93-6P 543710-95-8P 543710-97-0P
543710-99-2P 543711-01-9P 543711-04-2P
543711-06-4P 543711-08-6P 543711-11-1P
543711-13-3P 543711-15-5P 543711-17-7P
543711-19-9P 543711-21-3P 543711-24-6P
543711-27-9P 543711-29-1P 543711-31-5P
543711-33-7P 543711-35-9P 543711-38-2P
543711-40-6P 543711-42-8P 543711-44-0P
543711-46-2P 543711-48-4P 543711-50-8P
543711-52-0P 543711-57-5P 543711-59-7P
543711-60-0P 543711-62-2P 543711-63-3P
543711-68-8P 543711-70-2P 543711-72-4P
543711-74-6P 543711-76-8P 543711-78-0P
543711-80-4P 543711-82-6P 543711-84-8P
543711-86-0P 543711-88-2P 543711-90-6P
543711-92-8P 543711-94-0P 543711-95-1P
543711-97-3P 543711-99-5P 543712-01-2P
543712-03-4P 543712-05-6P 543712-07-8P
543712-09-0P 543712-11-4P 543712-13-6P
543712-15-8P 543712-17-0P 543712-18-1P
543712-20-5P 543712-22-7P 543712-24-9P
543712-26-1P 543712-28-3P 543712-30-7P
543712-32-9P 543712-34-1P 543712-36-3P
543712-38-5P 543712-40-9P 543712-42-1P
543712-44-3P 543712-46-5P 543712-48-7P
543712-50-1P 543712-52-3P 543712-54-5P
543712-56-7P 543712-58-9P 543712-61-4P
543712-63-6P 543712-65-8P 543712-67-0P
543712-69-2P 543712-71-6P 543712-75-0P
543712-77-2P 543712-79-4P 543713-64-0P
543713-65-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. as modulators of insulin-like growth factor-1 receptor (IGF-1))

RN 543710-62-9 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 543710-64-1 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543710-66-3 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543710-68-5 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543710-71-0 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543710-73-2 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-(2-methoxyphenyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543710-75-4 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N2-[[3-(2-methoxyphenyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543710-77-6 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543710-79-8 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543710-81-2 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 543710-83-4 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543710-85-6 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-ethyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543710-87-8 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[2-(2-furanyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543710-89-0 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543710-91-4 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543710-93-6 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543710-95-8 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543710-97-0 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[2-(1H-imidazol-4-yl)ethyl]-N4-(5-methyl-


1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543710-99-2 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-01-9 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-04-2 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-06-4 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(5-methylpyrazinyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-08-6 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-11-1 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-(2-chlorophenyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-13-3 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-(2-chlorophenyl)-5-isoxazolyl]methyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-15-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-17-7 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[2-(3-methyl-5-isoxazolyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-19-9 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N2-[[3-(2-chlorophenyl)-5-isoxazolyl]methyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-21-3 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-propyl-1H-pyrazol-3-yl)-N2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-24-6 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-27-9 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-ethyl-1H-pyrazol-3-yl)-N2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-29-1 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-ethyl-1H-pyrazol-3-yl)-N2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-31-5 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-propyl-1H-pyrazol-3-yl)-N2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 543711-33-7 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N2-[[3-(2-fluorophenyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-35-9 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-38-2 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[[3-[2-(trifluoromethoxy)phenyl]-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-40-6 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-42-8 CAPLUS
CN Benzonitrile, 2-[5-[[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]methyl]-3-isoxazolyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-44-0 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-(2-fluorophenyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-46-2 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[[3-(2-fluorophenyl)-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-48-4 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-50-8 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[[3-(2-fluorophenyl)-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-52-0 CAPLUS
CN Benzonitrile, 2-[5-[[[5-bromo-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]methyl]-3-isoxazolyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-57-5 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-(3-methyl-5-isoxazolyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-59-7 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-ethyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-60-0 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-62-2 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 543711-63-3 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[[3-(2-ethoxyphenyl)-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-68-8 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[[3-[2-(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-70-2 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[[3-(2-methylphenyl)-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-72-4 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[2-(3-pyridazinyl)ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-74-6 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-(2-bromophenyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-76-8 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[2-(4-pyrimidinyl)ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-78-0 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(pyrazinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-80-4 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[(5-methyl-3-isoxazolyl)methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-82-6 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-propyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-84-8 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-86-0 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-(2-methoxy-3-pyridinyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-88-2 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-(3-methyl-1H-pyrazol-4-yl)propyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-90-6 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[3-(3-methyl-1H-pyrazol-4-yl)propyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-92-8 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-94-0 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-95-1 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-97-3 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-(1H-imidazol-4-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543711-99-5 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N2-[[3-(3-methoxyphenyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-01-2 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[[3-(3-pyridinyl)-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-03-4 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-05-6 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-propyl-1H-pyrazol-3-yl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-07-8 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-09-0 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-ethyl-1H-pyrazol-3-yl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-11-4 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-13-6 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[(5-methyl-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-15-8 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-(3-furanylmethyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-17-0 CAPLUS
CN 2-Pyridinecarbonitrile, 5-[[[5-bromo-4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-18-1 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-20-5 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(3-furanylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-22-7 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[(6-methoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-24-9 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(5-bromo-3-pyridinyl)methyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-26-1 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(2-furanylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-28-3 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[2-(3-thienyl)ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-30-7 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-32-9 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-34-1 CAPLUS
CN 2,4-Pyrimidinediamine, N2-([2,4'-bipyridin]-2'-ylmethyl)-5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-36-3 CAPLUS
CN 2,4-Pyrimidinediamine, N2-([2,3'-bipyridin]-5'-ylmethyl)-5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-38-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-([2,3'-bipyridin]-5'-ylmethyl)-5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-40-9 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(6-chloro-2-pyridinyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-42-1 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[(3-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-44-3 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[(6-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-46-5 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(5,6-dimethyl-2-pyridinyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-48-7 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-50-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[1-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 543712-52-3 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[1-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 543712-54-5 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[1-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 543712-56-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[1-(3-pyridinyl)propyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-58-9 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[1-(2-pyridinyl)propyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-61-4 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[1-(3-pyridinyl)propyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-63-6 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(5-bromo-3-pyridinyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-65-8 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-67-0 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[2-(5-pyrimidinyl)ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-69-2 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-propyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-71-6 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-75-0 CAPLUS
CN Pyrrolidine, 1-[[5-[[[5-bromo-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]methyl]-3-isoxazolyl]carbonyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-77-2 CAPLUS
CN 3-Isoxazolemethanol, 5-[[[5-bromo-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543712-79-4 CAPLUS
CN 3-Isoxazolecarboxamide, 5-[[[5-bromo-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543713-64-0 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[1-(3-methyl-5-isoxazolyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 543713-65-1 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[1-(2-pyridinyl)propyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L17 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:261683 CAPLUS
DN 138:271699
TI Preparation of 2-phenylamino-4-(5-pyrazolylamino)pyrimidines as kinase inhibitors, in particular, as SRC kinase inhibitors
IN Dixon, Julie; Dumas, Jacques; Brennan, Catherine; Hatoum-Mokdad, Holia; Lee, Wendy; Sibley, Robert; Bear, Brian; Chandler, Brent; Miranda, Karl; Chen, Gang; Chen, Zhi; Brittelli, David; Clark, Roger B.
PA Bayer Corporation, USA
SO PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003026666	A1	20030403	WO 2002-US30984	20020926

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-325110P P 20010926
OS MARPAT 138:271699
AB The invention provides novel substituted 2,4-diaminopyrimidine compds. (shown as I; variables defined below; e.g. N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]phenyl]-2,4-pyrimidinediamine; L is a linker = -O-(CH2)1-4-, S(O)0-2-(CH2)1-4-, -N(R1)-(CH2)1-4, -(CH2)1-4-O-(CH2)1-4-, -N(R1)-C(O)-(CH2)1-4-, and diradicals of cyclopentanol, cyclohexanol, pyrrolidine and piperidine with the heteroatom as one radical center; G = NR5R6; alternatively, L = -OCH[(CH2)1-3-][(CH2)2-3-] or N[(CH2)2-][(CH2)2-] and G = NR1; other definitions are given in the claims) and pharmaceutical compns. thereof. The invention also provides methods of use of I and pharmaceutical compns. thereof as inhibitors of SRC kinase enzymes. Exemplary diseases that can be treated by the compds. of the invention include cell proliferative diseases, such as cancer and non-malignant cell proliferative diseases, osteoporosis and inflammatory diseases. Also provided are methods for preparing the compds. of the present invention. About 100 examples of I were found to inhibit SRC kinase with IC50 values less than 150 nM. Many general methods of preparation of I and several specific examples are included; characterization data are included for 260 examples of I. For example, N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]phenyl]-2,4-pyrimidinediamine was prepared in 70% yield from N-(3-tert-butyl-1H-pyrazol-5-yl)-2-chloro-4-pyrimidinamine and N-[2-(3-aminophenoxy)ethyl]-N,N-diethylamine; procedures for preparing the reactants are also included.
IT **503566-09-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]phenyl]-2,4-pyrimidinediamine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of phenylamino pyrazolylamino pyrimidines as SRC kinase inhibitors)

RN 503566-09-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
IT **503566-10-7P,** 4-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]-2-[2-(diethylamino)ethoxy]benzonitrile **503566-11-8P,** 4-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]-2-[2-(diethylamino)ethoxy]benzonitrile **503566-12-9P,** N2-[3-[2-(Diethylamino)ethoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-13-0P,** N2-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-14-1P,** N2-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-5-fluoro-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-15-2P,** 2-[2-(Diethylamino)ethoxy]-4-[[4-[(3-tert-pentyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]benzonitrile **503566-16-3P,** N2-[4-Methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-17-4P,** 5-Fluoro-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-18-5P,** N4-(3-tert-Pentyl-1H-pyrazol-5-yl)-N2-[3-[2-(1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-19-6P,** N2-[4-Methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-20-9P,** 5-Fluoro-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-21-0P,** N2-[3-[2-(4-Methyl-1-piperidinyl)ethoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-22-1P,** N2-[3-[(1-Methyl-3-piperidinyl)methoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-23-2P,** N2-[3-[2-(Diethylamino)ethoxy]phenyl]-N4-[3-(1-ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-2,4-pyrimidinediamine **503566-24-3P,** N2-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-N4-[3-(1-ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-2,4-pyrimidinediamine **503566-25-4P,** N2-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-N4-[3-(1-ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-5-fluoro-2,4-pyrimidinediamine **503566-26-5P,** 2-[2-(Diethylamino)ethoxy]-4-[[4-[[3-(1-ethyl-1-methylpropyl)-1H-pyrazol-5-yl]amino]-2-pyrimidinyl]amino]benzonitrile **503566-27-6P,** N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-28-7P,** N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-5-fluoro-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-29-8P,** N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-N2-[3-[2-(1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-30-1P,** N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-31-2P,** N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-5-fluoro-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]-

2,4-pyrimidinediamine **503566-32-3P**, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-N2-[3-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-33-4P**, N2-[3-[2-((3R,5S)-3,5-Dimethyl-1-piperidinyl)ethoxy]phenyl]-N4-[3-(1-ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-2,4-pyrimidinediamine **503566-34-5P**, N2-[3-[2-((3R,5S)-3,5-Dimethyl-1-piperidinyl)ethoxy]-4-methylphenyl]-N4-[3-(1-ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-2,4-pyrimidinediamine **503566-35-6P**, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503566-36-7P**, N4-(3-Cyclopropyl-1H-pyrazol-5-yl)-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503566-37-8P**, N4-(3-Cyclopropyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503566-38-9P**, N2-[3-[2-(Benzylamino)ethoxy]phenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-5-methyl-2,4-pyrimidinediamine **503566-39-0P**, N2-[3-[2-(Benzylamino)ethoxy]phenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-40-3P**, N2-[3-[2-(Benzylamino)ethoxy]phenyl]-5-bromo-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-41-4P**, N2-[3-[2-[Benzyl(2-methoxyethyl)amino]ethoxy]phenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-42-5P**, N2-[4-Bromo-3-[2-(diethylamino)ethoxy]phenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-43-6P**, N2-[4-Bromo-3-[2-(diethylamino)ethoxy]phenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-5-fluoro-2,4-pyrimidinediamine **503566-44-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-[(4-fluorophenyl)amino]ethoxy]phenyl]-2,4-pyrimidinediamine **503566-45-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-[(4-fluorophenyl)amino]ethoxy]phenyl]-2,4-pyrimidinediamine **503566-46-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-[(4-methoxyphenyl)amino]ethoxy]phenyl]-2,4-pyrimidinediamine **503566-47-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-[(4-methoxyphenyl)amino]ethoxy]phenyl]-2,4-pyrimidinediamine **503566-48-1P**, N2-[3-[2-(Benzothiazol-6-ylamino)ethoxy]phenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-49-2P**, N2-[3-[2-(1H-Benzimidazol-2-ylamino)ethoxy]phenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-50-5P**, N2-[3-[2-(1H-Benzimidazol-2-ylamino)ethoxy]phenyl]-5-fluoro-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-51-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(1H-indazol-5-ylamino)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-52-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(1H-indazol-5-ylamino)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-53-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-54-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-methyl-N2-[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-55-0P**, 5-Bromo-N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-56-1P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]-2,4-pyrimidinediamine **503566-57-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-((3R,5S)-3,5-dimethyl-1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-58-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-((3R,5S)-3,5-dimethyl-1-piperidinyl)ethoxy]phenyl]-5-fluoro-2,4-pyrimidinediamine **503566-59-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(cyclohexylamino)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-60-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(cyclohexylamino)ethoxy]phenyl]-5-fluoro-2,4-pyrimidinediamine **503566-61-8P**,

N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(2,2,6,6-tetramethyl-1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-62-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-((3R,5S)-3,5-dimethyl-1-piperidinyl)ethoxy]-4-methylphenyl]-2,4-pyrimidinediamine **503566-63-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-((3R,5S)-3,5-dimethyl-1-piperidinyl)ethoxy]-4-methylphenyl]-5-fluoro-2,4-pyrimidinediamine **503566-64-1P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-((2R,6S)-2,6-dimethyl-1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-65-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-((2R,6S)-2,6-dimethyl-1-piperidinyl)ethoxy]phenyl]-5-fluoro-2,4-pyrimidinediamine **503566-66-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-((3R,5R)-3,5-dimethyl-1-piperidinyl)ethoxy]-4-methylphenyl]-2,4-pyrimidinediamine **503566-67-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-68-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-69-6P**, N2-[3-[2-(4-Benzyl-1-piperidinyl)ethoxy]phenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-70-9P**, N2-[3-[2-(4-Benzyl-1-piperidinyl)ethoxy]phenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-5-fluoro-2,4-pyrimidinediamine **503566-71-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-72-1P**, 5-Bromo-N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-73-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]phenyl]-5-methyl-2,4-pyrimidinediamine **503566-74-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]phenyl]-5-fluoro-2,4-pyrimidinediamine **503566-75-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-76-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-chloro-N2-[3-[2-(diethylamino)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-77-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-chloro-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-78-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-chloro-3-[2-(diethylamino)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-79-8P**, 5-Bromo-N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-80-1P**, N2-[3-[2-(Benzylamino)ethoxy]phenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-5-fluoro-2,4-pyrimidinediamine **503566-81-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-methyl-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-82-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-2,4-pyrimidinediamine **503566-83-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-5-fluoro-2,4-pyrimidinediamine **503566-84-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-85-6P**, 1-[2-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenoxy]ethyl]-N,N-diethyl-3-piperidinecarboxamide **503566-86-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]-4-methylphenyl]-2,4-pyrimidinediamine **503566-87-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]-4-methylphenyl]-5-fluoro-2,4-pyrimidinediamine **503566-88-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[3-(diethylamino)propoxy]phenyl]-2,4-pyrimidinediamine **503566-89-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[3-(diethylamino)propoxy]phenyl]-5-fluoro-2,4-pyrimidinediamine **503566-90-3P**, N4-(3-tert'-Butyl-1H-pyrazol-5-yl)-5-fluoro-N-[4-methyl-3-[2-(4-

morpholinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-91-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methyl-3-[(1-methyl-2-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503566-92-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methyl-3-[(1-methyl-2-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503566-93-6P**, N2-[4-Methyl-3-[(1-methyl-2-piperidinyl)methoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-94-7P**, N-[5-Fluoro-2-[[4-methyl-3-[(1-methyl-2-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]-N-(3-tert-pentyl-1H-pyrazol-5-yl)amine **503566-95-8P**, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-N2-[4-methyl-3-[(1-methyl-2-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503566-96-9P**, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-5-fluoro-N2-[4-methyl-3-[(1-methyl-2-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503566-97-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503566-98-1P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503566-99-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503567-00-8P**, N2-[4-Methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503567-01-9P**, 5-Fluoro-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503567-02-0P**, N-[5-Fluoro-2-([3-[(1-methyl-3-piperidinyl)methoxy]phenyl]amino)-4-pyrimidinyl]-N-(3-tert-pentyl-1H-pyrazol-5-yl)amine **503567-03-1P**, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-5-fluoro-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503567-04-2P**, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-5-fluoro-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503567-05-3P**, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503567-06-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503567-07-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(1-methyl-2-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503567-08-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(1-methyl-2-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503567-09-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methoxy-3-[[2-(1-piperidinyl)cyclohexyl]oxy]phenyl]-2,4-pyrimidinediamine **503567-10-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methoxy-3-[[2-(1-piperidinyl)cyclohexyl]oxy]phenyl]-2,4-pyrimidinediamine **503567-11-1P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]-4-(4-methoxyphenoxy)phenyl]-5-fluoro-2,4-pyrimidinediamine **503567-12-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]-4-(3,4-dimethylphenoxy)phenyl]-2,4-pyrimidinediamine **503567-13-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]-4-(3,4-dimethylphenoxy)phenyl]-5-fluoro-2,4-pyrimidinediamine **503567-14-4P**, N2-[3-[2-(3-Azabicyclo[3.2.2]non-3-yl)ethoxy]-4-methylphenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-5-fluoro-2,4-pyrimidinediamine **503567-15-5P**, N2-[3-[2-(3-Azabicyclo[3.2.2]non-3-yl)ethoxy]-4-methylphenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503567-16-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-(4-methoxy-3-[2-[(2-methoxy-1-methylethyl)amino]ethoxy]phenyl)-2,4-pyrimidinediamine **503567-17-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-(3-[2-[(2-ethylbutyl)amino]ethoxy]-4-methoxyphenyl)-5-fluoro-2,4-pyrimidinediamine **503567-18-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-


[(cyclohexylmethyl)amino]ethoxy]phenyl]-2,4-pyrimidinediamine **503567-19-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-[(1-methylbutyl)amino]ethoxy]phenyl]-2,4-pyrimidinediamine **503567-20-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-[(4-methylcyclohexyl)amino]ethoxy]phenyl]-2,4-pyrimidinediamine **503567-21-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(cyclopentylamino)ethoxy]phenyl]-2,4-pyrimidinediamine **503567-22-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methoxy-3-[2-[(2-methoxy-1-methylethyl)amino]ethoxy]phenyl]-2,4-pyrimidinediamine **503567-23-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-(3-[2-[(2-ethylbutyl)amino]ethoxy]-4-methoxyphenyl)-2,4-pyrimidinediamine **503567-24-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methoxy-3-[2-(neopentylamino)ethoxy]phenyl]-2,4-pyrimidinediamine **503567-25-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methoxy-3-[2-(neopentylamino)ethoxy]phenyl]-2,4-pyrimidinediamine **503567-26-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methoxy-3-[2-[[2-(4-morpholinyl)ethyl]amino]ethoxy]phenyl]-2,4-pyrimidinediamine **503567-27-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methoxy-3-[2-[[2-(4-morpholinyl)ethyl]amino]ethoxy]phenyl]-2,4-pyrimidinediamine **503567-28-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(diethylamino)ethyl]amino]phenyl]-2,4-pyrimidinediamine **503567-29-1P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(diethylamino)ethyl]amino]phenyl]-5-methyl-2,4-pyrimidinediamine **503567-30-4P**, 5-Bromo-N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(diethylamino)ethyl]amino]phenyl]-2,4-pyrimidinediamine **503567-31-5P**, 5-Bromo-N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(4-morpholinyl)ethyl]amino]phenyl]-2,4-pyrimidinediamine **503567-32-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(4-morpholinyl)ethyl]amino]phenyl]-2,4-pyrimidinediamine **503567-33-7P**, N2-[3-[2-(Diethylamino)ethoxy]phenyl]-N4-(3-phenyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503567-34-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-methyl-N2-[3-[[2-(4-morpholinyl)ethyl]amino]phenyl]-2,4-pyrimidinediamine **503567-35-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(diethylamino)ethyl]amino]phenyl]-5-fluoro-2,4-pyrimidinediamine **503567-36-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-chloro-N2-[3-[[2-(diethylamino)ethyl]amino]phenyl]-2,4-pyrimidinediamine **503567-37-1P**, 3-[[2-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenoxy]ethyl]amino]benzoic acid **503567-38-2P**, 3-[[2-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]ethyl]amino]benzoic acid **503567-39-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(diethylamino)ethyl]sulfanyl]phenyl]-2,4-pyrimidinediamine **503567-40-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(diethylamino)ethyl]sulfanyl]phenyl]-5-fluoro-2,4-pyrimidinediamine **503567-41-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(diethylamino)ethyl]sulfonyl]phenyl]-2,4-pyrimidinediamine **503567-42-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(diethylamino)ethyl]sulfonyl]phenyl]-5-fluoro-2,4-pyrimidinediamine **503567-43-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503567-44-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diisopropylamino)ethoxy]phenyl]-2,4-pyrimidinediamine **503567-45-1P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(1-methyl-4-azepanyl)oxy]phenyl]-2,4-pyrimidinediamine **503567-46-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(1-methyl-4-azepanyl)oxy]phenyl]-2,4-pyrimidinediamine **503567-47-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503567-48-4P**,

N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503567-49-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503567-50-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diisopropylamino)ethoxy]phenyl]-5-fluoro-2,4-pyrimidinediamine **503567-51-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-[methyl(phenyl)amino]ethoxy]phenyl]-2,4-pyrimidinediamine **503567-52-0P**, 1-[2-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenoxy]ethyl]-2-pyrrolidinone **503567-53-1P**, 1-[2-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]ethyl]-2-pyrrolidinone **503567-54-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503567-55-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503567-56-4 P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(diethylamino)ethoxy]methyl]phenyl]-2,4-pyrimidinediamine **503567-57-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(diethylamino)ethoxy]methyl]phenyl]-5-fluoro-2,4-pyrimidinediamine **503567-58-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(diisopropylamino)ethoxy]methyl]phenyl]-2,4-pyrimidinediamine **503567-59-7P**, 1-[2-[5-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]-2-methoxyphenoxy]ethyl]-2-pyrrolidinone **503567-60-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(diisopropylamino)ethoxy]methyl]phenyl]-5-fluoro-2,4-pyrimidinediamine **503567-61-1P 503567-62-2P 503567-63-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diisopropylamino)ethoxy]-4-methoxyphenyl]-2,4-pyrimidinediamine **503567-64-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diisopropylamino)ethoxy]-4-methoxyphenyl]-5-fluoro-2,4-pyrimidinediamine **503567-65-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diisopropylamino)ethoxy]-4-methylphenyl]-2,4-pyrimidinediamine **503567-66-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diisopropylamino)ethoxy]-4-methylphenyl]-5-fluoro-2,4-pyrimidinediamine **503567-67-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methyl-3-[2-(1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503567-68-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methyl-3-[2-(1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503567-69-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503567-70-2P**, 1-[2-[[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]benzyl]oxy]ethyl]-2-pyrrolidinone **503567-71-3P**, 1-[2-[[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]benzyl]oxy]ethyl]-2-pyrrolidinone **503567-72-4P**, 1-[2-[[5-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]-2-methoxybenzyl]oxy]ethyl]-2-pyrrolidinone **503567-73-5P**, 1-[2-[[5-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]-2-methoxybenzyl]oxy]ethyl]-2-pyrrolidinone **503567-74-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(diethylamino)ethoxy]methyl]-4-methoxyphenyl]-2,4-pyrimidinediamine **503567-75-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(diethylamino)ethoxy]methyl]-4-methoxyphenyl]-5-fluoro-2,4-pyrimidinediamine **503567-76-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(diisopropylamino)ethoxy]methyl]-4-methoxyphenyl]-2,4-pyrimidinediamine **503567-77-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(diisopropylamino)ethoxy]methyl]-4-methoxyphenyl]-5-fluoro-2,4-pyrimidinediamine **503567-78-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methyl-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2,4-

pyrimidinediamine **503567-79-1P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-(4-morpholinylmethyl)phenyl]-2,4-pyrimidinediamine **503567-80-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-(4-morpholinylmethyl)phenyl]-2,4-pyrimidinediamine **503567-81-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methoxy-3-(4-morpholinylmethyl)phenyl]-2,4-pyrimidinediamine **503567-82-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methoxy-3-(4-morpholinylmethyl)phenyl]-2,4-pyrimidinediamine **503567-83-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]-2,4-pyrimidinediamine **503567-84-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]-2,4-pyrimidinediamine **503567-85-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methoxy-3-[(4-methyl-1-piperazinyl)methyl]phenyl]-2,4-pyrimidinediamine **503567-86-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methoxy-3-[(4-methyl-1-piperazinyl)methyl]phenyl]-2,4-pyrimidinediamine **503567-87-1P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503567-88-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503567-89-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503567-90-6P**, N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]-2-(4-morpholinyl)acetamide **503567-91-7P**, N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenyl]-2-(1-piperidinyl)acetamide **503567-92-8P**, N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]-2-(1-piperidinyl)acetamide **503567-93-9P**, N1-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenyl]-N2,N2-diethylglycinamide **503567-94-0P**, N1-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]-N2,N2-diethylglycinamide **503567-95-1P**, N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenyl]-2-(1-pyrrolidinyl)acetamide **503567-96-2P**, N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]-2-(1-pyrrolidinyl)acetamide **503567-97-3P**, N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenyl]-2-(4-morpholinyl)acetamide **503567-98-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(1-piperidinyl)ethyl]amino]phenyl]-2,4-pyrimidinediamine **503567-99-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[[2-(1-piperidinyl)ethyl]amino]phenyl]-2,4-pyrimidinediamine **503568-00-1P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[3-(diethylamino)propyl]-4-methoxyphenyl]-2,4-pyrimidinediamine **503568-01-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[3-(diethylamino)propyl]-4-methoxyphenyl]-5-fluoro-2,4-pyrimidinediamine **503568-02-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[3-(diethylamino)-1-propynyl]phenyl]-2,4-pyrimidinediamine **503568-03-4P**, 1-[2-[5-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]-2-methoxyphenoxy]ethyl]-2-pyrrolidinone **503568-04-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503568-05-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]-4-(1-pyrrolidinyl)phenyl]-5-fluoro-2,4-pyrimidinediamine **503568-06-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]-4-(1-pyrrolidinyl)phenyl]-2,4-pyrimidinediamine **503568-07-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-((2R,6R)-2,6-dimethyl-4-morpholinyl)ethoxy]-4-methylphenyl]-2,4-pyrimidinediamine **503568-08-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-((2R,6R)-


2,6-dimethyl-4-morpholinyl)ethoxy]-4-methylphenyl]-5-fluoro-2,4-pyrimidinediamine **503568-09-0P**, N2-[3-[2-[Butyl(ethyl)amino]ethoxy]-4-methylphenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503568-10-3P**, N2-[3-[2-[Benzyl(ethyl)amino]ethoxy]-4-methylphenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503568-11-4P**, N2-[3-[2-[Butyl(ethyl)amino]ethoxy]-4-methylphenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-5-fluoro-2,4-pyrimidinediamine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylamino pyrazolylamino pyrimidines as SRC kinase inhibitors)

RN 503566-10-7 CAPLUS
CN Benzonitrile, 2-[2-(diethylamino)ethoxy]-4-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503566-11-8 CAPLUS
CN Benzonitrile, 2-[2-(diethylamino)ethoxy]-4-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 503566-12-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-13-0 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-14-1 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-15-2 CAPLUS
CN Benzonitrile, 2-[2-(diethylamino)ethoxy]-4-[[4-[[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-16-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-17-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-18-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-N2-[3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-19-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-20-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-21-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-22-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-23-2 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-24-3 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-25-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-26-5 CAPLUS
CN Benzonitrile, 2-[2-(diethylamino)ethoxy]-4-[[4-[[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-27-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-28-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-29-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-N2-[3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-30-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-31-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-32-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-33-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-[(3S,5R)-3,5-dimethyl-1-piperidinyl]ethoxy]phenyl]-N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-34-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-[(3S,5R)-3,5-dimethyl-1-piperidinyl]ethoxy]-4-methylphenyl]-N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-35-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-36-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[3-[(1-methyl-


3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-37-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoro-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-38-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-methyl-N2-[3-[2-[(phenylmethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-39-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(phenylmethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-40-3 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(phenylmethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503566-41-4 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(2-methoxyethyl)(phenylmethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503566-42-5 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[4-bromo-3-[2-(diethylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503566-43-6 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[4-bromo-3-[2-(diethylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-44-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(4-fluorophenyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-45-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-[(4-fluorophenyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-46-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(4-methoxyphenyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-47-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-[(4-methoxyphenyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-48-1 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(6-benzothiazolylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-49-2 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(1H-benzimidazol-2-ylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-50-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(1H-benzimidazol-2-ylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-51-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-


(1H-indazol-5-ylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-52-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(1H-indazol-5-ylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-53-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-54-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-methyl-N2-[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-55-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-56-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-57-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(3R,5S)-3,5-dimethyl-1-piperidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-58-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(3R,5S)-3,5-dimethyl-1-piperidinyl]ethoxy]phenyl]-5-fluoro- (9CI) (CA

INDEX NAME)


Absolute stereochemistry.




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-59-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(cyclohexylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-60-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(cyclohexylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-61-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(2,2,6,6-tetramethyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-62-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(3R,5S)-3,5-dimethyl-1-piperidinyl]ethoxy]-4-methylphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-63-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(3R,5S)-3,5-dimethyl-1-piperidinyl]ethoxy]-4-methylphenyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-64-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(2R,6S)-2,6-dimethyl-1-piperidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-65-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(2R,6S)-2,6-dimethyl-1-piperidinyl]ethoxy]phenyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-66-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(3R,5R)-3,5-dimethyl-1-piperidinyl]ethoxy]-4-methylphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-67-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-68-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-69-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[4-(phenylmethyl)-1-piperidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-70-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-[4-(phenylmethyl)-1-piperidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-71-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-72-1 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-73-2 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-methyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-74-3 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-75-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-76-5 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-77-6 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-78-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[4-chloro-3-[2-(diethylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-79-8 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-80-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-[(phenylmethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-81-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-methyl-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-82-3 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-83-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 503566-84-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-85-6 CAPLUS
CN 3-Piperidinecarboxamide, 1-[2-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenoxy]ethyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-86-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-methylphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-87-8 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-methylphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-88-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[3-(diethylamino)propoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-89-0 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[3-(diethylamino)propoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-90-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-butyl-1H-pyrazol-3-yl)-5-fluoro-N2-[4-methyl-3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-91-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-


methyl-3-[(1-methyl-2-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-92-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methyl-3-[(1-methyl-2-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-93-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-N2-[4-methyl-3-[(1-methyl-2-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-94-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methyl-3-[(1-methyl-2-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-95-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-N2-[4-methyl-3-[(1-methyl-2-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-96-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methyl-3-[(1-methyl-2-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-97-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-98-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503566-99-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-00-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-01-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-02-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-03-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-04-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-05-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-06-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-07-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(1-methyl-2-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 503567-08-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(1-methyl-2-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-09-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[[2-(1-piperidinyl)cyclohexyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-10-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[[2-(1-piperidinyl)cyclohexyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-11-1 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-(4-methoxyphenoxy)phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-12-2 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-(3,4-dimethylphenoxy)phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-13-3 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-(3,4-dimethylphenoxy)phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-14-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(3-azabicyclo[3.2.2]non-3-yl)ethoxy]-4-methylphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-15-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(3-azabicyclo[3.2.2]non-3-yl)ethoxy]-4-methylphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-16-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[2-[(2-methoxy-1-methylethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-17-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(2-ethylbutyl)amino]ethoxy]-4-methoxyphenyl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-18-8 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-[(cyclohexylmethyl)amino]ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-19-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(1-methylbutyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-20-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(4-methylcyclohexyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-21-3 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(cyclopentylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-22-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[2-[(2-methoxy-1-methylethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-23-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(2-ethylbutyl)amino]ethoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-24-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(2,2-dimethylpropyl)amino]ethoxy]-4-methoxyphenyl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-25-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(2,2-dimethylpropyl)amino]ethoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-26-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[2-[[2-(4-morpholinyl)ethyl]amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-27-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[2-[[2-(4-morpholinyl)ethyl]amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-28-0 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[[2-(diethylamino)ethyl]amino]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-29-1 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[[2-(diethylamino)ethyl]amino]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-methyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-30-4 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-[[2-(diethylamino)ethyl]amino]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-31-5 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[[2-(4-morpholinyl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-32-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[[2-(4-morpholinyl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-33-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-34-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-methyl-N2-[3-[[2-(4-morpholinyl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-35-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[[2-(diethylamino)ethyl]amino]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-36-0 CAPLUS
CN 2,4-Pyrimidinediamine, 5-chloro-N2-[3-[[2-(diethylamino)ethyl]amino]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-37-1 CAPLUS
CN Benzoic acid, 3-[[2-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-38-2 CAPLUS
CN Benzoic acid, 3-[[2-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-39-3 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[[2-(diethylamino)ethyl]thio]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-40-6 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[[2-(diethylamino)ethyl]thio]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-41-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[[2-(diethylamino)ethyl]sulfonyl]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-42-8 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[[2-(diethylamino)ethyl]sulfonyl]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-43-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-44-0 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-45-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(hexahydro-1-methyl-1H-azepin-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-46-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(hexahydro-1-methyl-1H-azepin-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-47-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-48-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-49-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-50-8 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-51-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(methylphenylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-52-0 CAPLUS
CN 2-Pyrrolidinone, 1-[2-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-53-1 CAPLUS
CN 2-Pyrrolidinone, 1-[2-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-54-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-


(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-55-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-56-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[[2-(diethylamino)ethoxy]methyl]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-57-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[[2-(diethylamino)ethoxy]methyl]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-58-6 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[[2-[bis(1-methylethyl)amino]ethoxy]methyl]ph


enyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-59-7 CAPLUS
CN 2-Pyrrolidinone, 1-[2-[5-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]-2-methoxyphenoxy]ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-60-0 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[[2-[bis(1-methylethyl)amino]ethoxy]methyl]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-61-1 CAPLUS
CN 2-Pyrrolidinone, 1-[2-[5-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]-2-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-62-2 CAPLUS
CN 2-Pyrrolidinone, 1-[2-[5-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]-2-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-63-3 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-64-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-65-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methylphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-66-6 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methylphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-67-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-methyl-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-68-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methyl-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 503567-69-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-70-2 CAPLUS
CN 2-Pyrrolidinone, 1-[2-[[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]methoxy]ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-71-3 CAPLUS
CN 2-Pyrrolidinone, 1-[2-[[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]methoxy]ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-72-4 CAPLUS
CN 2-Pyrrolidinone, 1-[2-[[5-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]-2-methoxyphenyl]methoxy]ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-73-5 CAPLUS
CN 2-Pyrrolidinone, 1-[2-[[5-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]-2-methoxyphenyl]methoxy]ethyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-74-6 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[[2-(diethylamino)ethoxy]methyl]-4-methoxyphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-75-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[[2-(diethylamino)ethoxy]methyl]-4-methoxyphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-76-8 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[[2-[bis(1-methylethyl)amino]ethoxy]methyl]-4-methoxyphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-77-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[[2-[bis(1-methylethyl)amino]ethoxy]methyl]-4-methoxyphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-78-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-methyl-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-79-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-80-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-81-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-82-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-83-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-84-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-85-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-86-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-87-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-88-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-89-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-90-6 CAPLUS
CN 4-Morpholineacetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-91-7 CAPLUS
CN 1-Piperidineacetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-92-8 CAPLUS
CN 1-Piperidineacetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-93-9 CAPLUS
CN Acetamide, 2-(diethylamino)-N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-94-0 CAPLUS
CN Acetamide, 2-(diethylamino)-N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-95-1 CAPLUS
CN 1-Pyrrolidineacetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-96-2 CAPLUS
CN 1-Pyrrolidineacetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-97-3 CAPLUS
CN 4-Morpholineacetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-98-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[[2-(1-piperidinyl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503567-99-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[[2-(1-piperidinyl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-00-1 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[3-(diethylamino)propyl]-4-methoxyphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-01-2 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[3-(diethylamino)propyl]-4-methoxyphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-02-3 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[3-[3-(diethylamino)-1-propynyl]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503568-03-4 CAPLUS


CN 2-Pyrrolidinone, 1-[2-[5-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]-2-methoxyphenoxy]ethyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503568-04-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 503568-05-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-(1-pyrrolidinyl)phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503568-06-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-(1-pyrrolidinyl)phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-07-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(2R,6R)-2,6-dimethyl-4-morpholinyl]ethoxy]-4-methylphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-08-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(2R,6R)-2,6-dimethyl-4-morpholinyl]ethoxy]-4-methylphenyl]-5-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-09-0 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(butylethylamino)ethoxy]-4-methylphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-10-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[ethyl(phenylmethyl)amino]ethoxy]-4-methylphenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-11-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(butylethylamino)ethoxy]-4-methylphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX

NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

IT **503568-12-5P,** N2-[3-[2-[Benzyl(ethyl)amino]ethoxy]-4-methylphenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-5-fluoro-2,4-pyrimidinediamine **503568-13-6P,** N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-((2R,6S)-2,6-dimethyl-4-morpholinyl)ethoxy]-4-methylphenyl]-2,4-pyrimidinediamine **503568-14-7P,** N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-((2R,6S)-2,6-dimethyl-4-morpholinyl)ethoxy]-4-methylphenyl]-5-fluoro-2,4-pyrimidinediamine **503568-15-8P,** N2-[3-[2-(3-Azabicyclo[3.2.2]non-3-yl)ethoxy]-4-methylphenyl]-5-fluoro-N4-[3-(1-methylcyclopropyl)-1H-pyrazol-5-yl]-2,4-pyrimidinediamine **503568-16-9P,** N2-[3-[2-[Butyl(ethyl)amino]ethoxy]-4-methylphenyl]-5-fluoro-N4-[3-(1-methylcyclopropyl)-1H-pyrazol-5-yl]-2,4-pyrimidinediamine **503568-17-0P,** N2-[3-[2-[Benzyl(ethyl)amino]ethoxy]-4-methylphenyl]-5-fluoro-N4-[3-(1-methylcyclopropyl)-1H-pyrazol-5-yl]-2,4-pyrimidinediamine **503568-18-1P,** N2-[3-[2-((2R,6R)-2,6-Dimethyl-4-morpholinyl)ethoxy]-4-methylphenyl]-5-fluoro-N4-[3-(1-methylcyclopropyl)-1H-pyrazol-5-yl]-2,4-pyrimidinediamine **503568-19-2P,** N2-[3-[2-((2R,6S)-2,6-Dimethyl-4-morpholinyl)ethoxy]-4-methylphenyl]-5-fluoro-N4-[3-(1-methylcyclopropyl)-1H-pyrazol-5-yl]-2,4-pyrimidinediamine **503568-20-5P,** N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[5-[2-(diethylamino)ethoxy]-2-methylphenyl]-5-fluoro-2,4-pyrimidinediamine **503568-21-6P,** N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-[2-(diethylamino)ethoxy]phenyl]-5-methyl-2,4-pyrimidinediamine **503568-22-7P,** N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[5-[2-(diethylamino)ethoxy]-2-methylphenyl]-2,4-pyrimidinediamine **503568-23-8P,** N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[8-[2-(diethylamino)ethoxy]-6-quinolinyl]-2,4-pyrimidinediamine **503568-24-9P,** 5-Bromo-N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[4-[2-(diethylamino)ethoxy]phenyl]-2,4-pyrimidinediamine **503568-25-0P,** N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-(4-morpholinylmethyl)phenyl]-2,4-pyrimidinediamine **503568-26-1P,** N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-(4-morpholinylmethyl)phenyl]-2,4-pyrimidinediamine **503568-27-2P,** N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-[4-(1H-pyrrol-1-yl)-1-piperidinyl]phenyl]-2,4-pyrimidinediamine **503568-28-3P,** N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-(4-methyl-1-piperazinyl)phenyl]-2,4-pyrimidinediamine **503568-29-4P,** N2-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-N4-[3-(1-methylcyclopropyl)-1H-pyrazol-5-yl]-2,4-pyrimidinediamine **503568-30-7P,** N2-[3-[2-(Diethylamino)ethoxy]phenyl]-N4-[3-(trifluoromethyl)-1H-pyrazol-5-yl]-2,4-pyrimidinediamine **503568-31-8P,** N2-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-N4-[3-(trifluoromethyl)-1H-pyrazol-5-yl]-2,4-pyrimidinediamine **503568-32-9P,** N2-[3-[2-(Diethylamino)ethoxy]phenyl]-N4-(3-


neopentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503568-33-0P**, N2-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-N4-(3-neopentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503568-35-2P**, N4-(3-Cyclopropyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]phenyl]-2,4-pyrimidinediamine **503568-36-3P**, N4-(3-Cyclopropyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-2,4-pyrimidinediamine **503568-37-4P**, N4-(3-Cyclopentyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]phenyl]-2,4-pyrimidinediamine **503568-38-5P**, N4-(3-Cyclopentyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-2,4-pyrimidinediamine **503568-39-6P**, N4-[3-(1-Adamantyl)-1H-pyrazol-5-yl]-N2-[3-[2-(diethylamino)ethoxy]phenyl]-2,4-pyrimidinediamine **503568-40-9P**, N4-[3-(1-Adamantyl)-1H-pyrazol-5-yl]-N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-2,4-pyrimidinediamine **503568-41-0P**, N2-[3-[2-(Diethylamino)ethoxy]phenyl]-N4-[3-(2-furyl)-1H-pyrazol-5-yl]-2,4-pyrimidinediamine **503568-43-2P**, 3-(4-Chlorophenyl)-5-[[2-[[3-[2-(diethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-1H-pyrazole-4-carbonitrile **503568-49-8P**, N2-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-N4-(4-Bromo-3-phenyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503568-52-3P**, N2-[3-[2-(Diethylamino)ethoxy]phenyl]-N4-(1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503568-53-4P**, N2-[3-[2-(Diethylamino)ethoxy]phenyl]-N4-(3-methyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503568-54-5P**, N4-[3-(4-Chlorophenyl)-1H-pyrazol-5-yl]-N2-[3-[2-(diethylamino)ethoxy]phenyl]-2,4-pyrimidinediamine **503568-55-6P**, N2-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-N4-(1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503568-56-7P**, Ethyl 5-[[2-[[3-[2-(diethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-1H-pyrazole-4-carboxylate **503568-57-8P**, N4-[3-(4-Chlorophenyl)-1H-pyrazol-5-yl]-N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-2,4-pyrimidinediamine **503568-59-0P**, N2-[3-[2-(Diethylamino)ethoxy]phenyl]-N4-[3-(2-thienyl)-1H-pyrazol-5-yl]-2,4-pyrimidinediamine **503568-61-4P**, N2-[3-[2-(Diethylamino)ethoxy]phenyl]-N4-[3-(4-methylphenyl)-1H-pyrazol-5-yl]-2,4-pyrimidinediamine **503568-62-5P**, N4-[3-(5-tert-Butyl-2-methyl-3-furyl)-1H-pyrazol-5-yl]-N2-[3-[2-(diethylamino)ethoxy]phenyl]-2,4-pyrimidinediamine **503568-63-6P**, N4-(3-Cyclohexyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-2,4-pyrimidinediamine **503568-65-8P**, N2-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-N4-[3-[1-methyl-1-(1H-1,2,4-triazol-1-yl)ethyl]-1H-pyrazol-5-yl]-2,4-pyrimidinediamine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenylamino pyrazolylamino pyrimidines as SRC kinase inhibitors)


RN 503568-12-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[ethyl(phenylmethyl)amino]ethoxy]-4-methylphenyl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-13-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(2S,6R)-2,6-dimethyl-4-morpholinyl]ethoxy]-4-methylphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-14-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(2S,6R)-2,6-dimethyl-4-morpholinyl]ethoxy]-4-methylphenyl]-5-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-15-8 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(3-azabicyclo[3.2.2]non-3-yl)ethoxy]-4-methylphenyl]-5-fluoro-N4-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-16-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(butylethylamino)ethoxy]-4-methylphenyl]-5-fluoro-N4-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-17-0 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-[ethyl(phenylmethyl)amino]ethoxy]-4-methylphenyl]-5-fluoro-N4-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]- (9CI)

(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-18-1 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-[(2R,6R)-2,6-dimethyl-4-morpholinyl]ethoxy]-4-methylphenyl]-5-fluoro-N4-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-19-2 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]ethoxy]-4-methylphenyl]-5-fluoro-N4-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-20-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[5-[2-(diethylamino)ethoxy]-2-methylphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-21-6 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[4-[2-(diethylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-methyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-22-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[5-[2-(diethylamino)ethoxy]-2-methylphenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-23-8 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[8-[2-(diethylamino)ethoxy]-6-quinolinyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-24-9 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[2-(diethylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-25-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-26-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-27-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-[4-(1H-pyrrol-1-yl)-1-piperidinyl]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-28-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-29-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-N4-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-30-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-[5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-31-8 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-N4-[5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-32-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-[5-(2,2-dimethylpropyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-33-0 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-N4-[5-(2,2-dimethylpropyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-35-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[3-[2-(diethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-36-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-37-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopentyl-1H-pyrazol-3-yl)-N2-[3-[2-(diethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-38-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopentyl-1H-pyrazol-3-yl)-N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-39-6 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-(5-tricyclo[3.3.1.13,7]dec-1-yl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-40-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-N4-(5-tricyclo[3.3.1.13,7]dec-1-yl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-41-0 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-[5-(2-furanyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-43-2 CAPLUS
CN 1H-Pyrazole-4-carbonitrile, 5-(4-chlorophenyl)-3-[[2-[[3-[2-(diethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-49-8 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(4-bromo-5-phenyl-1H-pyrazol-3-yl)-N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-52-3 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-53-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-54-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-N2-[3-[2-(diethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-55-6 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-N4-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-56-7 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 3-[[2-[[3-[2-(diethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-57-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-59-0 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-[5-(2-thienyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-61-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-[5-(4-methylphenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503568-62-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-[5-[5-(1,1-


dimethylethyl)-2-methyl-3-furanyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503568-63-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclohexyl-1H-pyrazol-3-yl)-N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503568-65-8 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-N4-[5-[1-methyl-1-(1H-1,2,4-triazol-1-yl)ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


L17 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:261682 CAPLUS
DN 138:271698
TI Preparation of 2-phenylamino-4-(5-pyrazolylamino)pyrimidines as kinase inhibitors, in particular, SRC kinase inhibitors for treating cancers
IN Dixon, Julie; Scott, William J.; Dumas, Jacques; Brennan, Catherine; Hatoum-Mokdad, Holia
PA Bayer Corporation, USA
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003026665	A1	20030403	WO 2002-US30980	20020926


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-325110P P 20010926
OS MARPAT 138:271698
AB This application discloses and claims 5-substituted-2,4-diaminopyrimidines, (shown as I; e.g. 3-[3-[[4-[(3-tert-butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenoxy]-1,2-propanediol; R1 = C1-6 alkyl, C3-6 cycloalkyl, adamantyl, Ph, or a 5-membered heteroarom. containing a single heteroatom = N, O, and S; R2 = H, F, Cl, or C1-4 alkyl; R3 = H, halogen, O(C1-4 alkyl), or C1-6alkyl; R4 = halogen, NO2, C1-6 alkyl, NR5R6, O(CH2)1-4CO2R7, O(CH2)1-4C(O)NR5R6, N(R5)C(O)CH2OR8, OC(O)R9, C(O)NR5R6, CO2R7, CN, or O(C1-4alkyl) optionally substituted by OH or phenoxy; addnl. definitions are in the claims), pharmaceutical compns. containing them, a method of making them, and methods of using them for treatment of cancers. Eleven examples of I were found to inhibit SRC kinase with IC50 values less than 500 nM. Many general methods of preparation of I and several specific examples are included; characterization data are included for 35 examples of I. For example, 3-[3-[[4-[(3-tert-butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenoxy]-1,2-propanediol was prepared from N-(3-tert-butyl-1H-pyrazol-5-yl)-2-chloro-4-pyrimidinamine and 3-(3-aminophenoxy)-1,2-propanediol in 21% yield; prepns. of the reactants are also included.
IT **503538-09-8P**, tert-Butyl [3-[[4-[(3-tert-butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]acetate
503538-10-1P, tert-Butyl [3-[[4-[(3-tert-butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenoxy]acetate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of phenylamino pyrazolylamino pyrimidines as SRC kinase inhibitors for treating cancers)
RN 503538-09-8 CAPLUS
CN Acetic acid, [3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA

INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-10-1 CAPLUS
CN Acetic acid, [3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
IT **503537-99-3P**, 3-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenoxy]-1,2-propanediol **503538-00-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-(3-methylphenyl)-2,4-pyrimidinediamine **503538-01-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-(3-nitrophenyl)-2,4-pyrimidinediamine **503538-02-1P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-(3-chlorophenyl)-2,4-pyrimidinediamine **503538-03-2P**, N2-(4-Bromophenyl)-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503538-04-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-(3-nitrophenyl)-2,4-pyrimidinediamine **503538-05-4P**, N2-(3-Bromophenyl)-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503538-06-5P**, N2-(3-Bromophenyl)-N4-(3-tert-butyl-1H-pyrazol-5-yl)-5-fluoro-2,4-pyrimidinediamine **503538-07-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-(dimethylamino)phenyl]-2,4-pyrimidinediamine **503538-08-7P**, 2-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenoxy]ethanol **503538-11-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-(2-phenoxyethoxy)phenyl]-2,4-pyrimidinediamine **503538-12-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-(3-ethylphenyl)-5-fluoro-2,4-pyrimidinediamine **503538-13-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-(3-ethylphenyl)-2,4-pyrimidinediamine **503538-14-5P**, N2-(3-tert-Butylphenyl)-N4-(3-tert-butyl-1H-pyrazol-5-yl)-5-fluoro-2,4-pyrimidinediamine **503538-15-6P**, N2-(3-tert-Butylphenyl)-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503538-16-7P**, 2-[5-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]-2-methoxyphenoxy]ethanol **503538-17-8P**, 2-[5-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]-2-chlorophenoxy]ethanol **503538-18-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-(3-ethoxyphenyl)-2,4-pyrimidinediamine **503538-19-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-(3-methoxyphenyl)-2,4-pyrimidinediamine **503538-20-3P**,


N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-(3-isopropoxyphenyl)-2,4-pyrimidinediamine **503538-21-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-(2,3-dihydro-1-benzofuran-5-yl)-2,4-pyrimidinediamine **503538-22-5P**, 2-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenoxy]-N,N-diethylacetamide **503538-23-6P**, 2-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]-N,N-diethylacetamide **503538-24-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]-2,4-pyrimidinediamine **503538-25-8P**, N2-(3-Aminophenyl)-N4-(3-tert-butyl-1H-pyrazol-5-yl)-5-fluoro-2,4-pyrimidinediamine **503538-26-9P**, N2-(3-Aminophenyl)-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503538-27-0P**, 2-(Benzyloxy)-N-[3-[[4-[(3-tert-butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenyl]acetamide **503538-28-1P**, N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenyl]-2-phenoxyacetamide **503538-29-2P**, N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenyl]benzamide **503538-30-5P**, 2-(Benzyloxy)-N-[3-[[4-[(3-tert-butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]acetamide **503538-31-6P**, N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]-2-phenoxyacetamide **503538-32-7P**, [3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]acetic acid **503538-33-8P**, Butyl [3-[[4-[(3-tert-butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenoxy]acetate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylamino pyrazolylamino pyrimidines as SRC kinase inhibitors for treating cancers)

RN 503537-99-3 CAPLUS
CN 1,2-Propanediol, 3-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503538-00-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 503538-01-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-02-1 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-03-2 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-bromophenyl)-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-04-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 503538-05-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-bromophenyl)-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-06-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-bromophenyl)-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-07-6 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-(dimethylamino)phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-08-7 CAPLUS
CN Ethanol, 2-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-11-2 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-(2-phenoxyethoxy)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503538-12-3 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(3-ethylphenyl)-5-fluoro- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503538-13-4 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(3-ethylphenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503538-14-5 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[3-(1,1-dimethylethyl)phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503538-15-6 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[3-(1,1-dimethylethyl)phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-16-7 CAPLUS
CN Ethanol, 2-[5-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]-2-methoxyphenoxy]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-17-8 CAPLUS
CN Ethanol, 2-[2-chloro-5-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-18-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(3-ethoxyphenyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-19-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-20-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-21-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(2,3-dihydro-5-benzofuranyl)-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-22-5 CAPLUS
CN Acetamide, 2-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenoxy]-N,N-diethyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-23-6 CAPLUS


CN Acetamide, 2-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]-N,N-diethyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-24-7 CAPLUS
CN Morpholine, 4-[[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-25-8 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-aminophenyl)-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-26-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-aminophenyl)-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-27-0 CAPLUS


CN Acetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-28-1 CAPLUS
CN Acetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-29-2 CAPLUS
CN Benzamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-30-5 CAPLUS
CN Acetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503538-31-6 CAPLUS


CN Acetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503538-32-7 CAPLUS


CN Acetic acid, [3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503538-33-8 CAPLUS

CN Acetic acid, [3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenoxy]-, butyl ester (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:261681 CAPLUS
DN 138:271697
TI Preparation of 2-phenylamino-4-(5-pyrazolylamino)pyrimidines as kinase inhibitors, in particular, SRC kinase inhibitors
IN Dixon, Julie; Dumas, Jacques; Brennan, Catherine; Hatoum-Mokdad, Holia; Lee, Wendy; Sibley, Robert; Bear, Brian
PA Bayer Corporation, USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003026664	A1	20030403	WO 2002-US30836	20020926


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-325110P P 20010926
OS MARPAT 138:271697
AB The invention provides novel substituted 2,4-diaminopyrimidine compds. (shown as I; variables defined below; e.g. N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[4-(3-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine), pharmaceutical compns. containing them, a method of making them, and methods of using them for treatment of cell proliferative diseases such as cancer, and non-malignant cell proliferative diseases, as well as osteoporosis and inflammatory diseases. Fifty examples of I were found to inhibit SRC kinase with IC50 values less than 500 nM. Many general methods of preparation of I and several specific examples are included; characterization data are included for 101 examples of I. For example, N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[4-(3-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine was prepared in 4 steps starting with 3-benzylpyridine and involving intermediates 3-(4-nitrobenzyl)pyridine, 3-(4-aminobenzyl)pyridine, and N-(3-tert-butyl-1H-pyrazol-5-yl)-2-chloro-4-pyrimidinamine (from 2,4-dichloropyrimidine and 5-amino-3-tert-butylpyrazole). For I: Y1 = H or C1-4 alkyl. Y2 = CF3, C1-6 alkyl; C3-6 cycloalkyl; or Ph optionally substituted with halogen, C1-4 alkyl, or C1-4 alkoxy; n = 0-2; X = halogen or C1-4 alkyl; p = 0-2; Z = halogen, C1-4 alkyl, or C1-4 alkoxy; and q = 0-2. L = a chemical bond, C1-4 alkylene, O, O(C1-4 alkylene), CH(C1-6 alkoxy), S(O)0-2, S(O)0-2(C1-4 alkylene), (C1-4 alkylene)S(O)0-2, NH(C1-4 alkylene), C(O), or C(O)(C1-4 alkylene). D = pyridinyl, imidazolyl, thiazolyl, pyrrolyl, thienyl, pyrazolyl, furyl, thiadiazolyl, oxazolyl, or benzimidazolyl. The pyridinyl and benzimidazolyl groups D each may be optionally substituted by up to three substituents = C1-4 alkyl, OH, C1-4 alkoxy, CN, NR1R2, C(O)NR1R2, halogen, and CO2(C1-6 alkyl), in which R1 and R2 = H, C1-4 alkyl, and C3-6 cycloalkyl. Alternatively, R1 and R2 may be joined to form a 5-6 membered saturated heterocycle -NQ in which Q = O, S(O)0-2, N-Y1, or C(Y1)2.
IT **503473-34-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-(3-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of phenylamino pyrazolylamino pyrimidines as SRC kinase inhibitors)

RN 503473-34-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-(3-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


IT **503473-35-6P**, N2-[4-[Butoxy(3-pyridinyl)methyl]phenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503473-36-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(4-methyl-3-pyridinyl)methyl]phenyl]-2,4-pyrimidinediamine **503473-37-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(4-methyl-3-pyridinyl)methyl]phenyl]-2,4-pyrimidinediamine **503473-38-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-[[6-(4-morpholinyl)-3-pyridinyl]methyl]phenyl]-2,4-pyrimidinediamine **503473-39-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-[[6-(methylamino)-3-pyridinyl]methyl]phenyl]-2,4-pyrimidinediamine **503473-40-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-(1H-pyrazol-3-yl)phenyl]-2,4-pyrimidinediamine **503473-41-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-(1,3-thiazol-5-ylmethyl)phenyl]-2,4-pyrimidinediamine **503473-42-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-(1,2,3-thiadiazol-4-yl)phenyl]-2,4-pyrimidinediamine **503473-43-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(4-pyridinyl)ethyl]phenyl]-2,4-pyrimidinediamine **503473-44-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-[(4-pyridinylsulfanyl)methyl]phenyl]-2,4-pyrimidinediamine **503473-45-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-[(4-pyridinylmethyl)sulfanyl]phenyl]-2,4-pyrimidinediamine **503473-46-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-[(4-pyridinylmethyl)sulfanyl]phenyl]-2,4-pyrimidinediamine **503473-47-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-(4-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503473-48-1P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-(4-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503473-49-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-(3-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503473-50-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(2-pyridinylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-51-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(2-pyridinylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-52-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(3-pyridinylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-53-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(3-pyridinylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-54-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(4-pyridinylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-55-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(4-pyridinylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-56-1P**

, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[[(2-methyl-1H-imidazol-4-yl)methyl]amino]phenyl]-2,4-pyrimidinediamine **503473-57-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[(2-methyl-1H-imidazol-4-yl)methyl]amino]phenyl]-2,4-pyrimidinediamine **503473-58-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(1H-imidazol-2-ylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-59-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(1H-imidazol-2-ylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-60-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(2-pyridinyl)ethyl]phenyl]-2,4-pyrimidinediamine **503473-61-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(2-pyridinyl)ethyl]phenyl]-2,4-pyrimidinediamine **503473-62-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(3-furylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-63-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(3-thienylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-64-1P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[(1-methyl-1H-pyrrol-2-yl)methyl]amino]phenyl]-2,4-pyrimidinediamine **503473-65-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(1,3-thiazol-2-ylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-66-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(3-pyridinyl)ethyl]phenyl]-2,4-pyrimidinediamine **503473-67-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(3-pyridinyl)ethyl]phenyl]-2,4-pyrimidinediamine **503473-68-5P**, 3-[4-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenoxy]-N-methylbenzamide **503473-69-6P**, [3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenyl](4-pyridinyl)methanone **503473-70-9P**, [3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenyl](3-pyridinyl)methanone **503473-71-0P**, [3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl](3-pyridinyl)methanone **503473-72-1P**, [3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenyl](2-pyridinyl)methanone **503473-73-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-(3-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503473-74-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-(3-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503473-75-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-(4-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503473-76-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-(4-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503473-77-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-(2-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503473-78-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-(2-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503473-79-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methoxy-3-(3-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503473-80-1P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methoxy-3-(2-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503473-81-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methoxy-3-(2-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503473-82-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methoxy-3-(3-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503473-83-4P**, 1-[5-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]-2-methoxyphenyl]-2-(1H-imidazol-1-yl)ethanone **503473-84-5P**, 1-[5-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]-2-methylphenyl]-2-(1H-imidazol-1-yl)ethanone **503473-85-6P**, 1-[5-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]-2-methylphenyl]-2-(1H-imidazol-1-yl)ethanone **503473-86-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(1H-imidazol-1-yl)ethyl]amino]phenyl]-2,4-pyrimidinediamine **503473-87-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-(1H-imidazol-

1-ylmethyl)phenyl]-2,4-pyrimidinediamine **503473-88-9P**,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-(1H-imidazol-1-
ylmethyl)phenyl]-2,4-pyrimidinediamine **503473-89-0P**,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-(1H-imidazol-1-ylmethyl)-4-
methoxyphenyl]-2,4-pyrimidinediamine **503473-90-3P**,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-(1H-imidazol-1-ylmethyl)-
4-methoxyphenyl]-2,4-pyrimidinediamine **503473-91-4P**,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-(1H-imidazol-1-ylmethyl)phenyl]-
2,4-pyrimidinediamine **503473-92-5P**, N4-(3-tert-Butyl-1H-pyrazol-
5-yl)-5-fluoro-N2-[4-(1H-imidazol-1-ylmethyl)phenyl]-2,4-pyrimidinediamine
503473-93-6P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-(3-
pyridinylsulfanyl)phenyl]-2,4-pyrimidinediamine **503473-94-7P**,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]-
2,4-pyrimidinediamine **503473-95-8P**, N4-(3-tert-Butyl-1H-pyrazol-
5-yl)-N2-[4-chloro-3-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]-2,4-
pyrimidinediamine **503473-96-9P**, 1-[2-[3-[[4-[(5-tert-Butyl-1H-
pyrazol-3-yl)amino]-2-pyrimidinyl]amino]phenoxy]ethyl]-1H-benzimidazole-5-
carboxylic acid **503473-97-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-
N2-[3-(1,3-oxazol-5-yl)phenyl]-2,4-pyrimidinediamine **503473-98-1P**
, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-(3-pyridinyloxy)phenyl]-2,4-
pyrimidinediamine **503473-99-2P**, [3-[[4-[(3-tert-Butyl-1H-pyrazol-
5-yl)amino]-2-pyrimidinyl]amino]phenyl](6-methoxy-3-pyridinyl)methanone
503474-00-8P, 5-Bromo-N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[4-(3-
pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503474-01-9P**,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-methyl-N2-[4-(3-
pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503474-02-0P**,
5-[4-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]benzyl]-
2-pyridinol **503474-03-1P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-
[4-[(6-fluoro-3-pyridinyl)methyl]phenyl]-2,4-pyrimidinediamine
503474-04-2P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-[(6-
fluoro-3-pyridinyl)methyl]phenyl]-2,4-pyrimidinediamine
503474-05-3P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[3-(1H-
imidazol-1-yl)propyl]phenyl]-2,4-pyrimidinediamine **503474-06-4P**,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[3-(1H-imidazol-1-
yl)propyl]phenyl]-2,4-pyrimidinediamine **503474-07-5P**,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(1H-imidazol-1-
yl)ethoxy]phenyl]-2,4-pyrimidinediamine **503474-08-6P**,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(1H-imidazol-1-
yl)ethoxy]phenyl]-2,4-pyrimidinediamine **503474-09-7P**,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(1H-imidazol-1-
yl)ethoxy]phenyl]-5-methyl-2,4-pyrimidinediamine **503474-10-0P**,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-
methoxyphenyl]-2,4-pyrimidinediamine **503474-11-1P**,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(1H-imidazol-1-
yl)ethoxy]-4-methoxyphenyl]-2,4-pyrimidinediamine **503474-12-2P**,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-
methylphenyl]-2,4-pyrimidinediamine **503474-13-3P**,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(1H-imidazol-1-
yl)ethoxy]-4-methylphenyl]-2,4-pyrimidinediamine **503474-14-4P**,
3-[4-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]benzyl]-
2-pyridinecarbonitrile **503474-15-5P**, 3-[4-[[4-[(3-tert-Butyl-1H-
pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]benzyl]-2-
pyridinecarbonitrile **503474-16-6P**, 3-[4-[[4-[(3-tert-Butyl-1H-
pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]benzyl]-N-methyl-2-
pyridinecarboxamide **503474-17-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-
yl)-N2-(4-[[2-(4-morpholinylcarbonyl)-3-pyridinyl]methyl]phenyl)-2,4-
pyrimidinediamine **503474-18-8P**, Butyl 3-[4-[[4-[(3-tert-butyl-1H-
pyrazol-5-yl)amino]-2-pyrimidinyl]amino]benzyl]-2-pyridinecarboxylate


503474-19-9P, Butyl 4-[4-[[4-[(3-tert-butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]benzyl]-2-pyridinecarboxylate **503474-20-2P**, 4-[4-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]benzyl]-2-pyridinecarbonitrile **503474-21-3P**, 4-[4-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]benzyl]-2-pyridinecarbonitrile hydrochloride **503474-22-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[2-chloro-5-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-2,4-pyrimidinediamine **503474-23-5P**, N4-(3-Methyl-1H-pyrazol-5-yl)-N2-[4-(3-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503474-24-6P**, N4-[3-(4-Chlorophenyl)-1H-pyrazol-5-yl]-N2-[4-(3-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503474-26-8P**, N4-(3-tert-Pentyl-1H-pyrazol-5-yl)-N2-[4-(3-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503474-27-9P**, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-N2-[4-(3-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503474-28-0P**, N4-(3-Cyclopropyl-1H-pyrazol-5-yl)-N2-[4-(3-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503474-29-1P**, N2-[4-(3-Pyridinylmethyl)phenyl]-N4-[3-(trifluoromethyl)-1H-pyrazol-5-yl]-2,4-pyrimidinediamine **503474-30-4P**, N4-(3-Cyclopentyl-1H-pyrazol-5-yl)-N2-[4-(3-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503474-31-5P**, N4-(3-Neopentyl-1H-pyrazol-5-yl)-N2-[4-(3-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine **503474-32-6P**, 3-[4-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]benzyl]-N-methylisonicotinamide **503474-33-7P**, 5-[4-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]benzyl]-N-methyl-2-pyridinecarboxamide **503474-48-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-[2-(4-pyridinyl)ethyl]phenyl]-2,4-pyrimidinediamine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylamino pyrazolylamino pyrimidines as SRC kinase inhibitors)

RN 503473-35-6 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[4-(butoxy-3-pyridinylmethyl)phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 503473-36-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(4-methyl-3-pyridinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-37-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(4-methyl-3-pyridinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-38-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-[[6-(4-morpholinyl)-3-pyridinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-39-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-[[6-(methylamino)-3-pyridinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-40-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-(1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-41-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-(5-thiazolylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-42-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-(1,2,3-thiadiazol-4-yl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-43-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-[2-(4-pyridinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-44-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-[(4-pyridinylthio)methyl]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-45-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-[(4-pyridinylmethyl)thio]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-46-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-[(4-pyridinylmethyl)thio]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-47-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-(4-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-48-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-(4-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-49-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-(3-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-50-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(2-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-51-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(2-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-52-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(3-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-53-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(3-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-54-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(4-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-55-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(4-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-56-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[[(2-methyl-1H-imidazol-4-yl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-57-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[[(2-methyl-1H-imidazol-4-yl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-58-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(1H-imidazol-2-ylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-59-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(1H-imidazol-2-ylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-60-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(2-pyridinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-61-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(2-pyridinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-62-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(3-furanylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-63-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(3-thienylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-64-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[[(1-methyl-1H-pyrrol-2-yl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-65-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(2-thiazolylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-66-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(3-pyridinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-67-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(3-pyridinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-68-5 CAPLUS
CN Benzamide, 3-[4-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-69-6 CAPLUS
CN Methanone, [3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]-4-pyridinyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-70-9 CAPLUS
CN Methanone, [3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]-3-pyridinyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-71-0 CAPLUS
CN Methanone, [3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-


2-pyrimidinyl]amino]phenyl]-3-pyridinyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-72-1 CAPLUS
CN Methanone, [3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]-2-pyridinyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-73-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-(3-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-74-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-(3-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-75-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-(4-


pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-76-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-(4-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-77-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-(2-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-78-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-(2-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-79-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-


methoxy-3-(3-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-80-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-(2-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-81-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-(2-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-82-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-(3-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-83-4 CAPLUS
CN Ethanone, 1-[5-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-


pyrimidinyl]amino]-2-methoxyphenyl]-2-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503473-84-5 CAPLUS


CN Ethanone, 1-[5-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]-2-methylphenyl]-2-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503473-85-6 CAPLUS


CN Ethanone, 1-[5-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]-2-methylphenyl]-2-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 503473-86-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[[2-(1H-imidazol-1-yl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 503473-87-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-(1H-imidazol-1-ylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-88-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-(1H-imidazol-1-ylmethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-89-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-(1H-imidazol-1-ylmethyl)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-90-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-(1H-imidazol-1-ylmethyl)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503473-91-4 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-(1H-imidazol-1-ylmethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503473-92-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-(1H-imidazol-1-ylmethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503473-93-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-(3-pyridinylthio)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503473-94-7 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503473-95-8 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[4-chloro-3-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503473-96-9 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 1-[2-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503473-97-0 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503473-98-1 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-(3-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503473-99-2 CAPLUS


CN Methanone, [3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl](6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-00-8 CAPLUS
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-(3-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-01-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-methyl-N2-[4-(3-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-02-0 CAPLUS
CN 2(1H)-Pyridinone, 5-[[4-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-03-1 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-[(6-fluoro-3-pyridinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503474-04-2 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-[(6-fluoro-3-pyridinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503474-05-3 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[3-(1H-imidazol-1-yl)propyl]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503474-06-4 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[3-(1H-imidazol-1-yl)propyl]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503474-07-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503474-08-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503474-09-7 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-5-methyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503474-10-0 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503474-11-1 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503474-12-2 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methylphenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503474-13-3 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methylphenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503474-14-4 CAPLUS


CN 2-Pyridinecarbonitrile, 3-[[4-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-15-5 CAPLUS
CN 2-Pyridinecarbonitrile, 3-[[4-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-16-6 CAPLUS
CN 2-Pyridinecarboxamide, 3-[[4-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-17-7 CAPLUS
CN Morpholine, 4-[[3-[[4-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]methyl]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-18-8 CAPLUS


CN 2-Pyridinecarboxylic acid, 3-[[4-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]methyl]-, butyl ester (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503474-19-9 CAPLUS


CN 2-Pyridinecarboxylic acid, 4-[[4-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]methyl]-, butyl ester (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503474-20-2 CAPLUS


CN 2-Pyridinecarbonitrile, 4-[[4-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 503474-21-3 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[4-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-22-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[2-chloro-5-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-23-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2-[4-(3-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-24-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-N2-[4-(3-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-26-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-N2-[4-(3-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-27-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-N2-[4-(3-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-28-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[4-(3-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-29-1 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[4-(3-pyridinylmethyl)phenyl]-N4-[5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-30-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopentyl-1H-pyrazol-3-yl)-N2-[4-(3-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-31-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(2,2-dimethylpropyl)-1H-pyrazol-3-yl]-N2-[4-(3-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 503474-32-6 CAPLUS


CN 4-Pyridinecarboxamide, 3-[[4-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503474-33-7 CAPLUS


CN 2-Pyridinecarboxamide, 5-[[4-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 503474-48-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-pyridinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:615605 CAPLUS
DN 137:169539
TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treatment of cancer, diabetes, and Alzheimer's disease
IN Bebbington, David; Charrier, Jean-Damien; Golec, Julian M. C.; Miller, Andrew; Knegtel, Ronald
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 335 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062789	A1	20020815	WO 2001-US51031	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2002066461	A1	20020829	WO 2001-US49139	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2002068415	A1	20020906	WO 2001-US50312	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003004161	A1	20030102	US 2001-26975	20011219
	US 6653300	B2	20031125		
	US 2003036543	A1	20030220	US 2001-25164	20011219
	US 6664247	B2	20031216		
	US 2003055068	A1	20030320	US 2001-26967	20011219
	US 2003078275	A1	20030424	US 2001-27001	20011219
	US 6653301	B2	20031125		
	US 2003105090	A1	20030605	US 2001-26966	20011219
	EP 1345922	A1	20030924	EP 2001-271061	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 1345927	A1	20030924	EP 2001-994510	20011219

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

EP	1355905	A1	20031029	EP 2001-273861	20011219

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US	2003004164	A1	20030102	US 2001-34683	20011220
US	6656939	B2	20031202		
US	2003022885	A1	20030130	US 2001-34019	20011220
NO	2003002704	A	20030821	NO 2003-2704	20030613
NO	2003002736	A	20030818	NO 2003-2736	20030616
PRAI US	2000-257887P	P	20001221	} Appl. Priority	
US	2001-286949P	P	20010427		
WO	2001-US49139	W	20011219		
WO	2001-US50312	W	20011219		
WO	2001-US51031	W	20011219		


OS MARPAT 137:169539

AB 285 Title compds. I [wherein Z1 = N or CR8; Z2 = N or CH; and at least 1 of Z1 and Z2 = N; Rx and Ry = independently TR3 or LZR3; or C2RxRy = (un)substituted fused (hetero)cycle; Q = NR4, O, S, C(R6')2, 1,2-cyclo(prop/but)anediyl, or 1,3-cyclobutanediyl; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, or carbocyclyl; T = a bond or alkylidene chain (un)interrupted by O, S, NR4, CO, CONH, NHCO, SO2, SO2NH, NHSO2, CO2, OCO, OCONH, or NHCO2, with provisos; Z = alkylidene chain; L = O, S, SO, SO2, NR6SO2, SO2NR6, NR6, NR6CO, NR6CO2, NR6CONR6, NR6SO2NR6, NR6NR6, OCONR6, or W; R2 and R2a = independently R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, COR, CO2R, CO(CH2)0-1COR, NO2, CN, SO0-2R, N(R4)2, carbamoyl, sulfamoyl, OCOR, acylamino, hydrazino, ureido, etc.; R = independently H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl; R4 = independently R7, COR7, carboxy, CON(R7)2, or SO2R7; W = CO, CO2, CONR6, C(R6)2O, C(R6)2SO0-2, C(R6)2SO2NR6, C(R6)2NR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, or C(R6)2NR6CONR6; R6, R6', R7 = independently H or aliphatic; or N(R6)2 or N(R7)2 = independently heterocyclyl or heteroaryl; or C(R6')2 = carbocycle; R8 = R, halo, OR, COR, CO2R, COCOR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2] were prepared However, the claims pertain only to 3-(2-amino-4-pyrimidinylamino)-1H-pyrazoles, i.e. Z1 = Z2 = N, and Q = NH. I are protein kinase inhibitors, especially of Aurora-2 and GSK-3. For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in t-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 μM: GSK-3β (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).


IT **446881-34-1P**, N4-(5-Cyclopropyl-1H-pyrazol-3-yl)-N2-(1H-indazol-5-yl)-6-methylpyrimidine-2,4-diamine **446881-35-2P**, N2-Benzothiazol-6-yl-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methylpyrimidine-2,4-diamine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 446881-34-1 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-1H-indazol-5-yl-6-methyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 446881-35-2 CAPLUS
CN 2,4-Pyrimidinediamine, N2-6-benzothiazolyl-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
IT **438205-74-4P 438205-75-5P 438205-76-6P,** (5-Cyclopropyl-1H-pyrazol-3-yl)[2-(3-methylphenylamino)-6-phenylpyrimidin-4-yl]amine **438205-77-7P,** [2-(4-Cyanomethylphenylamino)-6-phenylpyrimidin-4-yl](5-cyclopropyl-1H-pyrazol-3-yl)amine **438205-78-8P 438205-79-9P 438205-80-2P 438205-81-3P,** (5-Methyl-1H-pyrazol-3-yl)[2-(4-sulfamoylphenylamino)-6-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl]amine **438205-82-4P 438205-83-5P,** [2-(Benzimidazol-2-ylamino)-6-ethylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine **438205-84-6P 438205-85-7P 438205-86-8P 438205-87-9P 438205-88-0P 438205-89-1P,** [2-(Benzimidazol-2-ylamino)-6-methylpyrimidin-4-yl](5-phenyl-1H-pyrazol-3-yl)amine **438205-90-4P**, [2-(Benzimidazol-2-ylamino)-6-methylpyrimidin-4-yl][5-(Furan-2-yl)-1H-pyrazol-3-yl]amine **438205-91-5P,** [2-(4-Chlorophenylamino)-6-methylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine **438205-93-7P 438205-94-8P 438205-95-9P 438205-96-0P,** [2-(Benzimidazol-2-ylamino)-6-methoxymethylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine **438205-97-1P 438205-98-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)
RN 438205-74-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2,6-diphenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-75-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2,6-diphenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-76-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-methylphenyl)-6-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-77-7 CAPLUS
CN Benzeneacetonitrile, 4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-78-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-phenyl-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-79-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-80-2 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-81-3 CAPLUS
CN Benzenesulfonamide, 4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(3,4,5-trimethoxyphenyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-82-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-83-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-2-yl-6-ethyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-84-6 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-6-methyl-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-85-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-6-ethyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-86-8 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-87-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-6-(3-nitrophenyl)-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-88-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-N2,6-diphenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-89-1 CAPLUS
CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-2-yl-6-methyl-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-90-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-2-yl-N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-91-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-6-methyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-93-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-5,6-dimethyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 438205-94-8 CAPLUS
CN 2,4-Pyrimidinediamine, 5,6-dimethyl-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-95-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-6-(methoxymethyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-96-0 CAPLUS
CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-2-yl-6-(methoxymethyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-97-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(methoxymethyl)-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-98-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl-(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:575069 CAPLUS
DN 137:109292
TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3,for treatment of cancer, diabetes, and Alzheimer's disease
IN Bebbington, David; Charrier, Jean-Damien; Davies, Robert; Golec, Julian; Kay, David; Knegtel, Ronald; Patel, Sanjay
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 337 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002059111	A2	20020801	WO 2001-US51120	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2002066461	A1	20020829	WO 2001-US49139	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2002068415	A1	20020906	WO 2001-US50312	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003004161	A1	20030102	US 2001-26975	20011219
	US 6653300	B2	20031125		
	US 2003036543	A1	20030220	US 2001-25164	20011219
	US 6664247	B2	20031216		
	US 2003055068	A1	20030320	US 2001-26967	20011219
	US 2003078275	A1	20030424	US 2001-27001	20011219
	US 6653301	B2	20031125		
	US 2003105090	A1	20030605	US 2001-26966	20011219
	EP 1345922	A1	20030924	EP 2001-271061	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 1345926	A2	20030924	EP 2001-993360	20011219

	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	BR 2001016493	A	20030930		BR 2001-16493	20011219
	EP 1355905	A1	20031029		EP 2001-273861	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	US 2003004164	A1	20030102		US 2001-34683	20011220
	US 6656939	B2	20031202			
	US 2003022885	A1	20030130		US 2001-34019	20011220
	NO 2003002670	A	20030815		NO 2003-2670	20030612
	NO 2003002704	A	20030821		NO 2003-2704	20030613
PRAI	US 2000-257887P	P	20001221			
	US 2001-286949P	P	20010427			
	WO 2001-US49139	W	20011219			
	WO 2001-US50312	W	20011219			
	WO 2001-US51120	W	20011219			

OS MARPAT 137:109292


AB Title compds. I [wherein Z1 = N or CR8; Z2 = N or CH; and at least 1 of Z1 and Z2 = N; Rx and Ry = independently TR3 or LZR3; or C2RxRy = (un)substituted fused (hetero)cycle; Q = NR4, O, S, C(6a)2, 1,2-cyclo(prop/but)anediyl, or 1,3-cyclobutanediyl; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, or carbocyclyl; T = a bond or alkylidene chain (un)interrupted by O, S, NR4, CO, CONH, NHCO, SO2, SO2NH, NHSO2, CO2, OCO, OCONH, or NHCO2, with provisos; Z = alkylidene chain; L = O, S, SO, SO2, NR6SO2, SO2NR6, NR6, NR6CO, NR6CO2, NR6CONR6, NR6SO2NR6, NR6NR6, OCONR6, or W; R2 and R2a = independently R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, COR, CO2R, CO(CH2)0-1COR, NO2, CN, SO0-2R, N(R4)2, carbamoyl, sulfamoyl, OCOR, acylamino, hydrazino, ureido, etc.; R = independently H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl; R4 = independently R7, COR7, carboxy, CON(R7)2, or SO2R7; W = CO, CO2, CONR6, C(R6)2O, C(R6)2SO0-2, C(R6)2SO2NR6, C(R6)2NR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, or C(R6)2NR6CONR6; R6, R6a, R7 = independently H or aliphatic; or N(R6)2 or N(R7)2 = independently heterocyclyl or heteroaryl; or C(R6a)2 = carbocycle; R8 = R, halo, OR, COR, CO2R, COCOR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2] were prepared I are protein kinase inhibitors, especially of Aurora-2 and GSK-3. For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in t-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 μM: GSK-3β (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).

IT **438205-74-4P 438205-75-5P 438205-76-6P**
438205-77-7P 438205-78-8P 438205-79-9P
438205-80-2P 438205-81-3P 438205-82-4P
438205-83-5P 438205-84-6P 438205-85-7P
438205-86-8P 438205-87-9P 438205-88-0P
438205-89-1P 438205-90-4P 438205-91-5P
438205-93-7P 438205-94-8P 438205-95-9P
438205-96-0P 438205-97-1P 438205-98-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as

protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438205-74-4 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2,6-diphenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 438205-75-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2,6-diphenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 438205-76-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-methylphenyl)-6-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 438205-77-7 CAPLUS


CN Benzeneacetonitrile, 4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-78-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-phenyl-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-79-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-80-2 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-81-3 CAPLUS
CN Benzenesulfonamide, 4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(3,4,5-trimethoxyphenyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-82-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-83-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-2-yl-6-ethyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-84-6 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-6-methyl-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-85-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-6-ethyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-86-8 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-87-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-6-(3-nitrophenyl)-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-88-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-N2,6-diphenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-89-1 CAPLUS
CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-2-yl-6-methyl-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-90-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-2-yl-N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-91-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-6-methyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-93-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-5,6-dimethyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 438205-94-8 CAPLUS
CN 2,4-Pyrimidinediamine, 5,6-dimethyl-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-95-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-6-(methoxymethyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-96-0 CAPLUS
CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-2-yl-6-(methoxymethyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-97-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(methoxymethyl)-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-98-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl-(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

L17 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:555487 CAPLUS
DN 137:125169
TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3
IN Bebbington, David; Charrier, Jean-Damien; Golec, Julian; Miller, Andrew; Knegtel, Ronald
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 333 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002057259	A2	20020725	WO 2001-US49401	20011219
	WO 2002057259	A3	20030424		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2002066461	A1	20020829	WO 2001-US49139	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2002068415	A1	20020906	WO 2001-US50312	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003004161	A1	20030102	US 2001-26975	20011219
	US 6653300	B2	20031125		
	US 2003036543	A1	20030220	US 2001-25164	20011219
	US 6664247	B2	20031216		
	US 2003055068	A1	20030320	US 2001-26967	20011219
	US 2003078275	A1	20030424	US 2001-27001	20011219
	US 6653301	B2	20031125		
	US 2003105090	A1	20030605	US 2001-26966	20011219
	EP 1345922	A1	20030924	EP 2001-271061	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 1353916	A2	20031022	EP 2001-994323	20011219

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

EP 1355905 A1 20031029 EP 2001-273861 20011219

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2001016411 A 20031111 BR 2001-16411 20011219

US 2003004164 A1 20030102 US 2001-34683 20011220

US 6656939 B2 20031202

US 2003022885 A1 20030130 US 2001-34019 20011220

NO 2003002703 A 20030819 NO 2003-2703 20030613

NO 2003002704 A 20030821 NO 2003-2704 20030613

PRAI US 2000-257887P P 20001221

US 2001-286949P P 20010427

WO 2001-US49139 W 20011219

WO 2001-US49401 W 20011219

WO 2001-US50312 W 20011219


OS MARPAT 137:125169

AB The title compds. I [Z1 = N, CR8; Z2 = N. CH; and at least one of Z1 and Z2 = N; Rb, Rc = TR3, LZR3; C2RbRc = (un)substituted fused (hetero)cycle; Q = NR4, O, S, etc.; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, carbocyclyl; T = a bond, alkylidene (un)interrupted by O, S, NR4, CO, etc.; Z = alkylidene; L = O, S, SO, SO2, etc.; R2, R2a = R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, etc.; R = H, (un)substituted aliphatic, (hetero)aryl, heterocyclyl; R4 = R7, COR7, SO2R7, etc.; W = CO, CO2, CONR6, etc.; R6, R7 = H, alkyl; or N(R6)2 or N(R7)2 = heterocyclyl, heteroaryl] were prepared For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in tert-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 μM: GSK-3β (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).


IT **438205-74-4P 438205-75-5P 438205-76-6P**
438205-77-7P 438205-78-8P 438205-79-9P
438205-80-2P 438205-81-3P 438205-82-4P
438205-83-5P 438205-84-6P 438205-85-7P
438205-86-8P 438205-87-9P 438205-88-0P
438205-89-1P 438205-90-4P 438205-91-5P
438205-93-7P 438205-94-8P 438205-95-9P
438205-96-0P 438205-97-1P 438205-98-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438205-74-4 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2,6-diphenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-75-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2,6-diphenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-76-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-methylphenyl)-6-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-77-7 CAPLUS
CN Benzeneacetonitrile, 4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-78-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-phenyl-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-79-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-80-2 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-81-3 CAPLUS
CN Benzenesulfonamide, 4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(3,4,5-trimethoxyphenyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-82-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-83-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-2-yl-6-ethyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-84-6 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-6-methyl-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-85-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-6-ethyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-86-8 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-87-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-6-(3-nitrophenyl)-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-88-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-N2,6-diphenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-89-1 CAPLUS
CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-2-yl-6-methyl-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-90-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-2-yl-N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-91-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-6-methyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-93-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-5,6-dimethyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 438205-94-8 CAPLUS
CN 2,4-Pyrimidinediamine, 5,6-dimethyl-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-95-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-6-(methoxymethyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-96-0 CAPLUS
CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-2-yl-6-(methoxymethyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-97-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(methoxymethyl)-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-98-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl-(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


L17 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:487556 CAPLUS
DN 137:47221
TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3,for treatment of cancer, diabetes, and Alzheimer's disease
IN Bebbington, David; Charrier, Jean-Damien; Davies, Robert; Everitt, Simon; Kay, David; Knegtel, Ronald; Patel, Sanjay
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 342 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050065	A2	20020627	WO 2001-US49140	20011219
	WO 2002050065	A3	20021024		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002034047	A5	20020701	AU 2002-34047	20011219
	WO 2002066461	A1	20020829	WO 2001-US49139	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2002068415	A1	20020906	WO 2001-US50312	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003004161	A1	20030102	US 2001-26975	20011219
	US 6653300	B2	20031125		
	US 2003036543	A1	20030220	US 2001-25164	20011219
	US 6664247	B2	20031216		
	US 2003055068	A1	20030320	US 2001-26967	20011219
	US 2003078275	A1	20030424	US 2001-27001	20011219
	US 6653301	B2	20031125		
	US 2003105090	A1	20030605	US 2001-26966	20011219
	EP 1345922	A1	20030924	EP 2001-271061	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
EP 1345925 A2 20030924 EP 2001-985059 20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
EP 1355905 A1 20031029 EP 2001-273861 20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2003004164 A1 20030102 US 2001-34683 20011220
US 6656939 B2 20031202
US 2003022885 A1 20030130 US 2001-34019 20011220
NO 2003002671 A 20030818 NO 2003-2671 20030612
NO 2003002704 A 20030821 NO 2003-2704 20030613
PRAI US 2000-257887P P 20001221
US 2001-286949P P 20010427
WO 2001-US49139 W 20011219
WO 2001-US49140 W 20011219
WO 2001-US50312 W 20011219
OS MARPAT 137:47221
AB Title compds. I [wherein Z1 = N or CR8; Z2 = N or CH; and at least 1 of Z1 and Z2 = N; Rx and Ry = independently TR3 or LZR3; or C2RxRy = (un)substituted fused (hetero)cycle; Q = NR4, O, S, C(6a)2, 1,2-cyclo(prop/but)anediyl, or 1,3-cyclobutanediyl; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, or carbocyclyl; T = a bond or alkylidene chain (un)interrupted by O, S, NR4, CO, CONH, NHCO, SO2, SO2NH, NHSO2, CO2, OCO, OCONH, or NHCO2, with provisos; Z = alkylidene chain; L = O, S, SO, SO2, NR6SO2, SO2NR6, NR6, NR6CO, NR6CO2, NR6CONR6, NR6SO2NR6, NR6NR6, OCONR6, or W; R2 and R2a = independently R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, COR, CO2R, CO(CH2)0-1COR, NO2, CN, SO0-2R, N(R4)2, carbamoyl, sulfamoyl, OCOR, acylamino, hydrazino, ureido, etc.; R = independently H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl; R4 = independently R7, COR7, carboxy, CON(R7)2, or SO2R7; W = CO, CO2, CONR6, C(R6)2O, C(R6)2SO0-2, C(R6)2SO2NR6, C(R6)2NR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, or C(R6)2NR6CONR6; R6, R6a, R7 = independently H or aliphatic; or N(R6)2 or N(R7)2 = independently heterocyclyl or heteroaryl; or C(R6a)2 = carbocycle; R8 = R, halo, OR, COR, CO2R, COCOR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2] were prepared I are protein kinase inhibitors, especially of Aurora-2 and GSK-3. For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in t-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 μM: GSK-3β (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).
IT **438205-74-4P 438205-75-5P 438205-76-6P,** (5-Cyclopropyl-1H-pyrazol-3-yl)[2-(3-methylphenylamino)-6-phenylpyrimidin-4-yl]amine **438205-77-7P,** [2-(4-Cyanomethylphenylamino)-6-phenylpyrimidin-4-yl](5-cyclopropyl-1H-pyrazol-3-yl)amine **438205-78-8P 438205-79-9P 438205-80-2P 438205-81-3P,** (5-Methyl-1H-pyrazol-3-yl)[2-(4-sulfamoylphenylamino)-6-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl]amine **438205-82-4P 438205-83-5P,** [2-(Benzimidazol-2-ylamino)-6-ethylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine **438205-84-6P 438205-85-7P 438205-86-8P 438205-87-9P 438205-88-0P 438205-89-1P,** [2-(Benzimidazol-2-ylamino)-6-


methylpyrimidin-4-yl](5-phenyl-1H-pyrazol-3-yl)amine **438205-90-4P**
, [2-(Benzimidazol-2-ylamino)-6-methylpyrimidin-4-yl][5-(Furan-2-yl)-1H-pyrazol-3-yl]amine **438205-91-5P**, [2-(4-Chlorophenylamino)-6-methylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine **438205-93-7P** **438205-94-8P** **438205-95-9P** **438205-96-0P**, [2-(Benzimidazol-2-ylamino)-6-methoxymethylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine **438205-97-1P** **438205-98-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438205-74-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2,6-diphenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 438205-75-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2,6-diphenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 438205-76-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-methylphenyl)-6-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-77-7 CAPLUS
CN Benzeneacetonitrile, 4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-78-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-phenyl-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-79-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-80-2 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-81-3 CAPLUS
CN Benzenesulfonamide, 4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(3,4,5-trimethoxyphenyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-82-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-83-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-2-yl-6-ethyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-84-6 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-6-methyl-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-85-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-6-ethyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-86-8 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-87-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-6-(3-nitrophenyl)-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-88-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-N2,6-diphenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-89-1 CAPLUS
CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-2-yl-6-methyl-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-90-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-2-yl-N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-91-5 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-6-methyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-93-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-5,6-dimethyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-94-8 CAPLUS
CN 2,4-Pyrimidinediamine, 5,6-dimethyl-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-95-9 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-6-(methoxymethyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-96-0 CAPLUS
CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-2-yl-6-(methoxymethyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-97-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(methoxymethyl)-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 438205-98-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

L17 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:661403 CAPLUS
DN 135:227010
TI Preparation of 2,4-di(hetero)arylamino(oxy)-5-substituted pyrimidines as antineoplastic agents
IN Pease, Elizabeth Janet; Breault, Gloria Anne; Williams, Emma Jane; Bradbury, Robert Hugh; Morris, Jeffrey James
PA Astrazeneca Ab, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064655	A1	20010907	WO 2001-GB824	20010226
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001033976	A5	20010912	AU 2001-33976	20010226
	BR 2001008834	A	20021210	BR 2001-8834	20010226
	EP 1268444	A1	20030102	EP 2001-906018	20010226
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003525278	T2	20030826	JP 2001-563497	20010226
	US 2003149266	A1	20030807	US 2002-203154	20020806
	US 6649608	B2	20031118		
	NO 2002004153	A	20021029	NO 2002-4153	20020830
PRAI	GB 2000-4890	A	20000301		
	WO 2001-GB824	W	20010226		

OS MARPAT 135:227010
AB The title compds. [I; Q1, Q2 = (un)substituted aryl or carbon linked heteroaryl; and one or both Q1 and Q2 are substituted on a ring carbon by (CH2)nY(CH2)mZ or II (Y = NHCO, CONH; Z = (un)substituted cycloalkyl, Ph, heterocyclyl, etc.; n = 0-1; m = 1-3; Q3 = (un)substituted nitrogen linked heterocycle); G = O, NR2; R2 = H, alkyl, alkenyl, etc.; R1 = H, halo, OH, etc.] and their pharmaceutically acceptable salts, useful as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors, were prepared and formulated. Thus, reacting 4-anilino-2,5-dichloropyrimidine with 4-aminobenzoic acid followed by amidation of the resulting 4-anilino-2-(4-carboxyanilino)-5-chloropyrimidine with 1-(3-aminopropyl)imidazole afforded III [X = Cl; R = 3-(imidazol-1-yl)propylamino]. E.g., the title compound III [X = Br; R = 2-(piperidino)ethylamino] showed IC50 of 0.235 μM when tested in vitro assay for the CDK4 inhibitory activity.
IT **358789-01-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,4-di(hetero)arylamino(oxy)-5-substituted pyrimidines as antineoplastic agents)
RN 358789-01-2 CAPLUS

CN Benzamide, 4-[[5-bromo-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:617995 CAPLUS
DN 135:180783
TI Preparation of arylaminopyrimidines as Kinase inhibitors
IN Armistead, David M.; Bemis, Jean E.; Di Pietro, Lucian V.; Geuns-Meyer, Stephanie D.; Habgood, Gregory J.; Kim, Joseph L.; Nunes, Joseph J.; Patel, Vinod F.; Toledo-Sherman, Leticia M.
PA Amgen Inc., USA
SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060816	A1	20010823	WO 2001-US4983	20010216
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002052386	A1	20020502	US 2001-785599	20010216
	US 2003004174	A9	20030102		
	EP 1257546	A1	20021120	EP 2001-909266	20010216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003532635	T2	20031105	JP 2001-560200	20010216
	US 2003199534	A1	20031023	US 2003-353507	20030128
PRAI	US 2000-183256P	P	20000217		
	US 2001-785599	B1	20010216		
	US 2001-785999	A	20010216		
	WO 2001-US4983	W	20010216		

OS MARPAT 135:180783
AB Arylaminopyrimidines I wherein R1 and R2 are independently aryl, 5-8 membered monocyclic, 11-14 membered bicyclic, 1-9-heteroatoms tricyclic, substituted amine, sulfide, alkoxy, acyl, heterocycle, were prepared as Kinase inhibitors useful for treating disease or disease symptoms. Thus, pyrimidine II was prepared and tested in vitro as kinases inhibitor (FGFR1-1, IC50 < 1.5 μM).
IT **354817-37-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of triazine Kinase inhibitors)
RN 354817-37-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:457043 CAPLUS
DN 133:89537
TI Preparation of 2,4-pyrimidinediamine derivatives as anticancer agents
IN Bradbury, Robert Hugh; Breault, Gloria Anne; Jewsbury, Philip John; Pease, Janet Elizabeth
PA Astrazeneca UK Limited, UK
SO PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039101	A1	20000706	WO 1999-GB4325	19991220
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1140860	A1	20011010	EP 1999-962375	19991220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9916590	A	20011023	BR 1999-16590	19991220
	JP 2002533446	T2	20021008	JP 2000-591012	19991220
	AU 763091	B2	20030710	AU 2000-18743	19991220
	NZ 512118	A	20030829	NZ 1999-512118	19991220
	ZA 2001004413	A	20020829	ZA 2001-4413	20010529
	NO 2001003038	A	20010822	NO 2001-3038	20010619
	US 6593326	B1	20030715	US 2001-868602	20010823
PRAI	GB 1998-28511	A	19981224		
	WO 1999-GB4325	W	19991220		

OS MARPAT 133:89537
AB The present invention relates to the title compds. (I) [wherein R1 = H, (un)substituted alkyl, alkenyl, or alkynyl, benzyl, 2-phenylethyl, phthalimidoalkyl, or cycloalkylalkyl; Rx = halo, OH, NO2, NH2, CN, SH, CO2H, SO2NH2, NHCHO, ureido, etc.; Q1 and Q2 = independently (un)substituted aryl, 5- or 6-membered monocycle, or 9- or 10-membered bicyclic heterocycle], processes for their manufacture, and pharmaceutical compns. containing them. For example, addition of 4-[2-hydroxy-3-(N,N-dimethylamino)propoxy]aniline•HCl in MeOH to 5-bromo-2-chloro-4-(indan-5-ylamino)pyrimidine in BuOH (prepns. given) and heating to 100°C for 18 h gave II (42%). I inhibited the effects of cylin-dependent serine/threonine kinases (CDKs), showing selectivity for CDK2 (no data), CDK4 (IC50 ranging from 0.02 μM to 0.07 μM), and CDK6 (no data). In a tyrosine kinase activity assay using Sf21 cells transfected with plaque-pure FAK recombinant virus, I also inhibited focal adhesion kinase 3 (FAK3) with IC50 ranging from 0.032 μM to 0.07 μM. Typical IC50 values for I when tested for inhibition of cell growth in an Sulforhodamine B (SRB) assay were in the range of 1 mM to 1 nM. Thus, I possess anti-cancer properties, including anti-cell-migration, antiproliferation and/or apoptotic properties. Such properties are expected to be of value in the treatment of disease states associated with aberrant cell cycles and cell proliferation such as cancers (solid tumors

and leukemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, hemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases, and ocular diseases with retinal vessel proliferation.


IT **280580-25-8P 280580-63-4P 280580-64-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,4-pyrimidinediamine anticancer agents by coupling halopyrimidines with anilines and optional derivatization)

RN 280580-25-8 CAPLUS
CN 2-Propanol, 1-[4-[[5-bromo-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]phenoxy]-3-(dimethylamino)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 280580-63-4 CAPLUS
CN 2-Propanol, 1-[4-[[5-bromo-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 280580-64-5 CAPLUS
CN 2-Propanol, 1-[4-[[5-bromo-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]phenoxy]-3-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> => d his

     (FILE 'HOME' ENTERED AT 07:59:31 ON 11 MAR 2004)

     FILE 'REGISTRY' ENTERED AT 07:59:37 ON 11 MAR 2004
L1                SCREEN 1839
L2                SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L3                STRUCTURE UPLOADED
L4                QUE L3 AND L1 NOT L2
L5             23 S L4 SSS SAM
L6                SCREEN 1839
L7                SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L8                STRUCTURE UPLOADED
L9                QUE L8 AND L6 NOT L7
L10            24 S L9 SSS SAM
L11               SCREEN 1839
L12               SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L13               STRUCTURE UPLOADED
L14               QUE L13 AND L11 NOT L12
L15            23 S L14 SSS SAM
L16           518 S L14 SSS FUL

     FILE 'CAPLUS' ENTERED AT 08:06:15 ON 11 MAR 2004
L17            11 S L16

     FILE 'CAOLD' ENTERED AT 08:07:30 ON 11 MAR 2004

=> s l16
L18             0 L16

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.42     213.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -7.62

STN INTERNATIONAL LOGOFF AT 08:07:45 ON 11 MAR 2004
```